Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Jul. 31, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $.01 par value
Security Exchange Name	NASDAQ
Entity File Number	001-35331
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2492228
Entity Address, Address Line One	6100 Tower Circle
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	861-6000
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		88,524,535

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 43,541	$ 50,510
Accounts receivable, net	346,489	318,087
Other current assets	81,464	81,820
Total current assets	471,494	450,417
Property and equipment, net	3,164,076	3,107,766
Goodwill	2,435,025	2,396,412
Intangible assets, net	89,613	88,990
Deferred tax assets	3,404	3,468
Derivative instrument assets	72,965	60,524
Operating lease right-of-use assets	491,551
Other assets	62,290	64,927
Total assets	6,790,418	6,172,504
Current liabilities:
Current portion of long-term debt	38,895	34,112
Accounts payable	115,651	117,740
Accrued salaries and benefits	110,445	113,299
Current portion of operating lease liabilities	27,578
Other accrued liabilities	138,119	151,226
Total current liabilities	430,688	416,377
Long-term debt	3,206,868	3,159,375
Deferred tax liabilities	83,096	80,372
Operating lease liabilities	490,903
Other liabilities	124,310	154,267
Total liabilities	4,335,865	3,810,391
Redeemable noncontrolling interests	32,207	28,806
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 87,645,258 and 87,444,473 issued and outstanding at June 30, 2019 and December 31, 2018, respectively	876	874
Additional paid-in capital	2,550,653	2,541,987
Accumulated other comprehensive loss	(459,617)	(462,377)
Retained earnings	330,434	252,823
Total equity	2,422,346	2,333,307
Total liabilities and equity	$ 6,790,418	$ 6,172,504

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	87,645,258	87,444,473
Common stock, shares outstanding	87,645,258	87,444,473

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended						6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenue	$ 789,362				$ 765,738		$ 1,549,979	$ 1,507,979
Salaries, wages and benefits (including equity-based compensation expense of $4,182, $7,129, $10,283 and $14,048, respectively)	430,219				416,741		859,798	828,269
Professional fees	58,429				53,461		115,436	107,479
Supplies	30,914				30,133		60,871	59,497
Rents and leases	20,419				20,236		40,726	40,524
Other operating expenses	94,677				87,282		188,542	175,513
Depreciation and amortization	41,077				39,928		81,657	79,701
Interest expense, net	48,610				45,812		96,740	91,055
Debt extinguishment costs								940
Transaction-related expenses	5,212				2,887		9,533	7,655
Total expenses	729,557				696,480		1,453,303	1,390,633
Income before income taxes	59,805				69,258		96,676	117,346
Provision for income taxes	11,604				10,368		18,964	7,582
Net income	48,201				58,890		77,712	109,764
Net income attributable to noncontrolling interests	(61)				(54)		(101)	(109)
Net income attributable to Acadia Healthcare Company, Inc.	$ 48,140	$ 29,471	$ (331,637)	$ 46,232	$ 58,836	$ 50,819	$ 77,611	$ 109,655
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.55				$ 0.67		$ 0.89	$ 1.26
Diluted	$ 0.55				$ 0.67		$ 0.88	$ 1.26
Weighted-average shares outstanding:
Basic	87,618				87,303		87,562	87,205
Diluted	87,837				87,467		87,770	87,351

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 48,201	$ 58,890	$ 77,712	$ 109,764
Other comprehensive income (loss):
Foreign currency translation loss	(50,618)	(143,599)	(6,137)	(50,819)
Gain on derivative instruments, net of tax of $9.2 million, $10.5 million, $5.7 million and $3.2 million, respectively	17,587	29,107	8,897	9,054
Other comprehensive (loss) income	(33,031)	(114,492)	2,760	(41,765)
Comprehensive income (loss)	15,170	(55,602)	80,472	67,999
Comprehensive income attributable to noncontrolling interests	(61)	(54)	(101)	(109)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$ 15,109	$ (55,656)	$ 80,371	$ 67,890

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2017	$ 2,572,871	$ 871	$ 2,517,545	$ (374,118)	$ 428,573
Balance, shares at Dec. 31, 2017		87,060,000
Common stock issued under stock incentive plans	96	$ 2	94
Common stock issued under stock incentive plans, shares		228,000
Common stock withheld for minimum statutory taxes	(2,126)		(2,126)
Equity-based compensation expense	6,919		6,919
Other comprehensive income (loss)	72,727			72,727
Other	313		313
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	50,819				50,819
Balance at Mar. 31, 2018	2,701,619	$ 873	2,522,745	(301,391)	479,392
Balance, shares at Mar. 31, 2018		87,288,000
Balance at Dec. 31, 2017	2,572,871	$ 871	2,517,545	(374,118)	428,573
Balance, shares at Dec. 31, 2017		87,060,000
Other comprehensive income (loss)	(41,765)
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	109,655
Balance at Jun. 30, 2018	2,653,301	$ 873	2,530,083	(415,883)	538,228
Balance, shares at Jun. 30, 2018		87,330,000
Balance at Dec. 31, 2017	$ 2,572,871	$ 871	2,517,545	(374,118)	428,573
Balance, shares at Dec. 31, 2017		87,060,000
Common stock issued under stock incentive plans, shares	20,989
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	2,541,987	(462,377)	252,823
Balance, shares at Dec. 31, 2018	87,444,473	87,444,000
Balance at Mar. 31, 2018	$ 2,701,619	$ 873	2,522,745	(301,391)	479,392
Balance, shares at Mar. 31, 2018		87,288,000
Common stock issued under stock incentive plans	128		128
Common stock issued under stock incentive plans, shares		42,000
Common stock withheld for minimum statutory taxes	(232)		(232)
Equity-based compensation expense	7,129		7,129
Other comprehensive income (loss)	(114,492)			(114,492)
Other	313		313
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	58,836				58,836
Balance at Jun. 30, 2018	2,653,301	$ 873	2,530,083	(415,883)	538,228
Balance, shares at Jun. 30, 2018		87,330,000
Common stock issued under stock incentive plans	20	$ 1	19
Common stock issued under stock incentive plans, shares		33,000
Common stock withheld for minimum statutory taxes	(158)		(158)
Equity-based compensation expense	5,225		5,225
Other comprehensive income (loss)	(24,579)			(24,579)
Other	208		208
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	46,232				46,232
Balance at Sep. 30, 2018	2,680,249	$ 874	2,535,377	(440,462)	584,460
Balance, shares at Sep. 30, 2018		87,363,000
Common stock issued under stock incentive plans	130		130
Common stock issued under stock incentive plans, shares		81,000
Common stock withheld for minimum statutory taxes	(1,265)		(1,265)
Equity-based compensation expense	2,728		2,728
Other comprehensive income (loss)	(21,915)			(21,915)
Other	5,017		5,017
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	(331,637)				(331,637)
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	2,541,987	(462,377)	252,823
Balance, shares at Dec. 31, 2018	87,444,473	87,444,000
Common stock issued under stock incentive plans	$ 293	$ 2	291
Common stock issued under stock incentive plans, shares		149,000
Common stock withheld for minimum statutory taxes	(1,620)		(1,620)
Equity-based compensation expense	6,101		6,101
Other comprehensive income (loss)	35,791			35,791
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	29,471				29,471
Balance at Mar. 31, 2019	2,403,343	$ 876	2,546,759	(426,586)	282,294
Balance, shares at Mar. 31, 2019		87,593
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	2,541,987	(462,377)	252,823
Balance, shares at Dec. 31, 2018	87,444,473	87,444,000
Common stock issued under stock incentive plans, shares	42,545
Other comprehensive income (loss)	$ 2,760
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	77,611
Balance at Jun. 30, 2019	$ 2,422,346	$ 876	2,550,653	(459,617)	330,434
Balance, shares at Jun. 30, 2019	87,645,258	87,645
Balance at Mar. 31, 2019	$ 2,403,343	$ 876	2,546,759	(426,586)	282,294
Balance, shares at Mar. 31, 2019		87,593
Common stock issued under stock incentive plans	68		68
Common stock issued under stock incentive plans, shares		52,000
Common stock withheld for minimum statutory taxes	(356)		(356)
Equity-based compensation expense	4,182		4,182
Other comprehensive income (loss)	(33,031)			(33,031)
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	48,140				48,140
Balance at Jun. 30, 2019	$ 2,422,346	$ 876	$ 2,550,653	$ (459,617)	$ 330,434
Balance, shares at Jun. 30, 2019	87,645,258	87,645

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Operating activities:
Net income	$ 77,712
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Depreciation and amortization	81,657
Amortization of debt issuance costs	5,887
Equity-based compensation expense	10,283
Deferred income taxes	(205)
Other	2,395
Change in operating assets and liabilities:
Accounts receivable, net	(27,669)
Other current assets	(10,591)
Other assets	661
Accounts payable and other accrued liabilities	(11,060)
Accrued salaries and benefits	(3,232)
Other liabilities	2,848
Net cash provided by continuing operating activities	128,686
Net cash provided by operating activities	128,686
Investing activities:
Cash paid for acquisitions, net of cash acquired	(44,900)
Cash paid for capital expenditures	(139,128)
Cash paid for real estate acquisitions	(4,448)
Other	10,494
Net cash used in investing activities	(177,982)
Financing activities:
Borrowings on revolving credit facility	76,573
Principal payments on revolving credit facility	(11,573)
Principal payments on long-term debt	(16,492)
Common stock withheld for minimum statutory taxes, net	(1,615)
Other	(4,345)
Net cash provided by (used in) financing activities	42,548
Effect of exchange rate changes on cash	(221)
Net (decrease) increase in cash and cash equivalents	(6,969)
Cash and cash equivalents at beginning of the period	50,510
Cash and cash equivalents at end of the period	43,541
Effect of acquisitions:
Assets acquired, excluding cash	48,555
Liabilities assumed	(3,655)
Cash paid for acquisitions, net of cash acquired	$ 44,900

Description of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1.	Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (“U.S.”), the United Kingdom (“U.K.”) and Puerto Rico. At June 30, 2019, the Company operated 595 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the U.K. and Puerto Rico.

During the six months ended June 30, 2019, the Company commenced a review of strategic alternatives including those related to its U.K. operations and a potential sale of such operations. The likelihood and form of strategic alternative that the Company may pursue for its U.K. operations remains uncertain.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2019. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Certain reclassifications have been made to prior years to conform to the current year presentation.

Recently Issued Accounting Standards

6 Months Ended

Jun. 30, 2019

Accounting Changes And Error Corrections [Abstract]

Recently Issued Accounting Standards

2.	Recently Issued Accounting Standards

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) ASU 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”). ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-402 to determine which implementation costs to capitalize as assets. ASU 2018-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. Management is evaluating the impact of ASU 2018-15 on the Company’s consolidated financial statements.

In August 2017, FASB issued ASU 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”). ASU 2017-12 amends the hedge accounting model to enable entities to better portray the economics of their risk management activities in the financial statements and simplifies the application of hedge accounting in certain situations. ASU 2017-12 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company adopted ASU 2017-02 on January 1, 2019. There is no significant impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU 2016-02, “Leases” (“ASU 2016-02”). ASU 2016-02’s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. ASU 2016-02 requires application either retrospectively to each prior reporting period presented in the financial statements or retrospectively at the beginning of the period of adoption. The Company adopted ASU 2016-02 retrospectively at the beginning of the period of adoption. Prior periods have not been adjusted. On January 1, 2019, the Company recorded right-of-use assets and lease liabilities of $500.3 million and $526.6 million, respectively, as described in Note 8 – Leases.

Revenue

6 Months Ended

Jun. 30, 2019

Revenue From Contract With Customer [Abstract]

Revenue

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in Accounting Standards Codification (“ASC”) ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

The Company disaggregates revenue from contracts with customers by service type and by payor within each of the Company’s segments.

U.S. Facilities

The Company’s facilities in the United States (the “U.S. Facilities”) and services provided by the U.S. Facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; residential treatment centers; and outpatient community-based facilities.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

Outpatient community-based facilities. Outpatient community-based programs are designed to provide therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric or chemical dependency disorder while enabling the youth to remain at home and within their community.

The table below presents total U.S. revenue attributed to each category (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Acute inpatient psychiatric facilities	$	229,128	$	203,535	$	445,725	$	399,426
Specialty treatment facilities		201,269		192,894		394,304		377,429
Residential treatment centers		74,084		74,133		147,308		145,690
Outpatient community-based facilities		5,332		10,908		10,436		21,330
Revenue	$	509,813	$	481,470	$	997,773	$	943,875

The Company receives payments from the following sources for services rendered in our U.S. Facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); and (iv) individual patients and clients.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of our U.S. Facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the condensed consolidating statements of income. Bad debt expense for the three and six months ended June 30, 2019 and 2018 was not significant.

The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2019					2018					2019					2018
	Amount		%			Amount		%			Amount		%			Amount		%
Commercial	$	146,917		28.8	%	$	147,279		30.6	%	$	286,344		28.7	%	$	284,898		30.2	%
Medicare		73,505		14.4	%		69,343		14.4	%		146,121		14.6	%		136,557		14.5	%
Medicaid		255,070		50.0	%		225,732		46.9	%		494,261		49.5	%		439,068		46.5	%
Self-Pay		29,624		5.8	%		33,379		6.9	%		61,356		6.2	%		70,286		7.4	%
Other		4,697		1.0	%		5,737		1.2	%		9,691		1.0	%		13,066		1.4	%
Revenue	$	509,813		100.0	%	$	481,470		100.0	%	$	997,773		100.0	%	$	943,875		100.0	%

U.K. Facilities

The Company’s facilities located in the United Kingdom (the “U.K. Facilities”) and services provided by the U.K. Facilities can generally be classified into the following categories: healthcare facilities; education and children’s services; and adult care facilities.

Healthcare facilities. Healthcare facilities provide psychiatric treatment and nursing for sufferers of mental disorders, including for patients whose risk of harm to others and risk of escape from hospitals cannot be managed safely within other mental health settings. In order to manage the risks involved with treating patients, the facility is managed through the application of a range of security measures depending on the level of dependency and risk exhibited by the patient.

Education and children’s services. Education and children’s services provide specialist education for children and young people with special educational needs, including autism, Asperger’s Syndrome, social, emotional and mental health, and specific learning difficulties, such as dyslexia. The division also offers standalone children’s homes for children that require 52-week residential care to support complex and challenging behavior and fostering services.

Adult care facilities. Adult care focuses on care of individuals with a variety of learning difficulties, mental health illnesses and adult autism spectrum disorders. It also includes long-term, short-term and respite nursing care to high-dependency elderly individuals who are physically frail or suffering from dementia. Care is provided in a number of settings, including in residential care homes and through supported living.

The table below presents total U.K. revenue attributed to each category (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Healthcare facilities	$	155,553	$	158,894	$	307,261	$	313,509
Education and Children’s Services		46,142		48,065		92,264		96,150
Adult Care facilities		77,854		77,309		152,681		154,445
Revenue	$	279,549	$	284,268	$	552,206	$	564,104

On an annual basis, the Company receives payments from approximately 500 public funded sources in the U.K. (including the National Health Service (“NHS”), Clinical Commissioning Groups (“CCGs”) and local authorities in England, Scotland and Wales) and individual patients and clients. The Company determines the transaction price based on established billing rates by payor reduced by implicit price concessions. Implicit price concessions are insignificant in the U.K. Facilities.

The following table presents revenue by payor type and as a percentage of revenue in our U.K. Facilities (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2019					2018					2019					2018
	Amount		%			Amount		%			Amount		%			Amount		%
U.K. public funded sources	$	252,332		90.3	%	$	256,881		90.4	%	$	497,745		90.1	%	$	510,175		90.4	%
Self-Pay		26,651		9.5	%		27,272		9.6	%		53,465		9.7	%		52,340		9.3	%
Other		566		0.2	%		115		0.0	%		996		0.2	%		1,589		0.3	%
Revenue	$	279,549		100.0	%	$	284,268		100.0	%	$	552,206		100.0	%	$	564,104		100.0	%

The Company’s contract liabilities primarily consist of unearned revenue in our U.K. Facilities due to the timing of payments received mainly in our education and children’s services and healthcare facilities. Contract liabilities are included in other accrued liabilities on the condensed consolidated balance sheets. A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands):

Balance at December 31, 2018	$	31,239
Payments received		87,690
Revenue recognized		(83,456	)
Foreign currency translation loss		(747	)
Balance at June 30, 2019	$	34,726

Earnings Per Share

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Earnings Per Share

4.	Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2019 and 2018 (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$	48,140	$	58,836	$	77,611	$	109,655
Denominator:
Weighted average shares outstanding for basic earnings per share		87,618		87,303		87,562		87,205
Effect of dilutive instruments		219		164		208		146
Shares used in computing diluted earnings per common share		87,837		87,467		87,770		87,351
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$	0.55	$	0.67	$	0.89	$	1.26
Diluted	$	0.55	$	0.67	$	0.88	$	1.26

Approximately 1.9 million and 1.6 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three months ended June 30, 2019 and 2018, respectively, because their effect would have been anti-dilutive. Approximately 2.4 million and 2.0 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the six months ended June 30, 2019 and 2018, respectively, because their effect would have been anti-dilutive.

Acquisitions

6 Months Ended

Jun. 30, 2019

Business Combinations [Abstract]

Acquisitions

5.	Acquisitions

The Company’s strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations.

On April 1, 2019, the Company completed the acquisition of Bradford Recovery Center (“Bradford”), a specialty treatment facility with 46 beds located in Millerton, Pennsylvania for cash consideration of approximately $4.5 million.

On February 15, 2019, the Company completed the acquisition of Whittier Pavilion (“Whittier”), an inpatient psychiatric facility with 71 beds located in Haverhill, Massachusetts, for cash consideration of approximately $17.9 million. Also on February 15, 2019, the Company completed the acquisition of Mission Treatment (“Mission Treatment”) for cash consideration of approximately $22.5 million. Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona and Oklahoma.

Transaction-related expenses

Transaction-related expenses primarily relate to termination, restructuring, strategic review and other acquisition-related costs. Transaction-related expenses for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Termination, restructuring and strategic review costs	$	4,792	$	2,009	$	8,317	$	5,401
Legal, accounting and other acquisition-related costs		420		878		1,216		2,254
	$	5,212	$	2,887	$	9,533	$	7,655

Property and Equipment

6 Months Ended

Jun. 30, 2019

Property Plant And Equipment [Abstract]

Property and Equipment

6.	Property and Equipment

Property and equipment consisted of the following at June 30, 2019 and December 31, 2018 (in thousands):

	June 30, 2019			December 31, 2018
Land	$	446,795		$	430,771
Building and improvements		2,591,815			2,423,594
Equipment		469,107			444,538
Construction in progress		199,836			294,848
		3,707,553			3,593,751
Less: accumulated depreciation		(543,477	)		(485,985	)
Property and equipment, net	$	3,164,076		$	3,107,766

During the six months ended June 30, 2019, the Company closed a 168-bed residential treatment center in Albuquerque, New Mexico. The Company is currently evaluating options for the future use of this property. Additionally, the Company has recorded assets held for sale of $10.9 million and $17.0 million within other assets on the condensed consolidated balance sheets at June 30, 2019 and December 31, 2018, respectively.

Other Intangible Assets

6 Months Ended

Jun. 30, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Other Intangible Assets

7.	Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following at June 30, 2019 and December 31, 2018 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	June 30, 2019		December 31, 2018		June 30, 2019			December 31, 2018
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(2,100	)
Non-compete agreements		1,147		1,147		(1,147	)		(1,147	)
		3,247		3,247		(3,247	)		(3,247	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,599		12,343		—			—
Trade names		60,039		60,109		—			—
Certificates of need		16,975		16,538		—			—
		89,613		88,990		—			—
Total	$	92,860	$	92,237	$	(3,247	)	$	(3,247	)

All the Company’s definite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Leases

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases

The Company’s lease portfolio primarily consists of finance and operating real estate leases integral for facility operations. The original terms of the leases typically range from five to 30 years with optional renewal periods. A minimal portion of the Company’s lease portfolio consists of non-real estate leases, including copiers and equipment, which generally have lease terms of one to three years and have insignificant lease obligations.

In March 2016, the FASB issued ASU 2016-02. ASU 2016-02’s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 retrospectively at the beginning of the period of adoption. Prior periods have not been adjusted.

The Company has elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs. The Company also elected the accounting policy practical expedients by class of underlying asset to: (i) combine associated lease and non-lease components into a single lease component; and (ii) exclude recording short-term leases as right-of-use assets and liabilities on the condensed consolidated balance sheets. Non-lease components, which are not significant overall, are combined with lease components.

On January 1, 2019, the Company recorded right-of-use assets and lease liabilities on the condensed consolidated balance sheet of $500.3 million and $526.6 million, respectively, for non-cancelable real estate operating leases with original lease terms in excess of one year. Finance leases remained on the condensed consolidating balance sheets as required by previous accounting guidance. The Company reviews service agreements for embedded leases and records right-of-use assets and liabilities as necessary.

Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for prepayments, accrued lease payments, lease incentives and initial direct costs. Certain of the Company’s leases include renewal or termination options. Calculation of operating lease right-of-use assets and liabilities include the initial lease term unless it is reasonably certain a renewal or termination option will be exercised. Variable components of lease payments fluctuating with a future index or rate, as well as those related to common area maintenance costs, are not included in determining lease payments and are expensed as incurred. Most of the Company’s leases do not contain implicit borrowing rates, and therefore, incremental borrowing rates were calculated based on information available at the later of the lease commencement date or January 1, 2019. Incremental borrowing rates reflect the Company’s estimated interest rates for collateralized borrowings over similar lease terms.

Lease Position

At June 30, 2019, the Company recorded the following on the condensed consolidated balance sheet (in thousands):

Right-of-Use Assets	Balance Sheet Classification	June 30, 2019
Finance lease right-of-use assets	Property and equipment, net	$	44,981
Operating lease right-of-use assets	Operating lease right-of-use assets		491,551
Total		$	536,532

Lease Liabilities	Balance Sheet Classification	June 30, 2019
Current:
Finance lease liabilities	Other accrued liabilities	$	7,095
Operating lease liabilities	Current portion of operating lease liabilities		27,578
Noncurrent:
Finance lease liabilities	Other liabilities		44,088
Operating lease liabilities	Operating lease liabilities		490,903
Total		$	569,664

Weighted-average remaining lease terms and discount rates at June 30, 2019 were as follows:


Weighted-average remaining lease term (in years):
Finance	7.2
Operating	19.7

Weighted-average discount rate:
Finance		6.4	%
Operating		6.4	%

Lease Costs

The Company recorded the following lease costs for the three and six months ended June 30, 2019 (in thousands):

	Three Months Ended June 30, 2019		Six Months Ended June 30, 2019
Finance lease costs:
Depreciation of leased assets		1,136		2,259
Interest of lease liabilities		999		1,996
Total finance lease costs	$	2,135	$	4,255

Operating lease costs		16,237		32,766
Variable lease costs		1,044		1,930
Short term lease costs		1,483		2,930
Other lease costs		1,655		3,100
Total rents and leases	$	20,419	$	40,726

Total lease costs	$	22,554	$	44,981

Other

Undiscounted cash flows for finance and operating leases recorded on the condensed consolidated balance sheet were as follows at June 30, 2019 (in thousands):

	Finance Leases		Operating Leases
For the six months ending December 31, 2019	$	4,137	$	30,201
2020		6,938		58,325
2021		35,101		54,702
2022		2,193		50,007
2023		1,063		46,511
Thereafter		26,094		708,139
Total minimum lease payments		75,526		947,885
Less: amount of lease payments representing interest		24,343		429,404
Present value of future minimum lease payments		51,183		518,481
Less: Current portion of lease liabilities		7,095		27,578
Noncurrent lease liabilities	$	44,088	$	490,903

Supplemental data for the six months ended June 30, 2019 was as follows (in thousands):

	Six Months Ended June 30,
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	31,212
Operating cash flows for finance leases	$	1,996
Financing cash flows for finance leases	$	1,684

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	10,674
Finance leases	$	1,774

Long-Term Debt

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Long-Term Debt

9.	Long-Term Debt

Long-term debt consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans	$	356,250		$	365,750
Senior Secured Term B Loans		1,365,920			1,372,912
Senior Secured Revolving Line of Credit		65,000			—
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
Other long-term debt		5,396			5,953
Less: unamortized debt issuance costs, discount and premium		(36,803	)		(41,128	)
		3,245,763			3,193,487
Less: current portion		(38,895	)		(34,112	)
Long-term debt	$	3,206,868		$	3,159,375

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”). The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the SEC.

On March 22, 2018, the Company entered into a Second Repricing Facilities Amendment (the “Second Repricing Facilities Amendment”) to the Amended and Restated Credit Agreement. The Second Repricing Facilities Amendment (i) replaced the Term Loan B Facility Tranche B-1 (the “Tranche B-1 Facility”) and the Term Loan B Facility Tranche B-2 (the “Tranche B-2 Facility”) with a new Term Loan B facility Tranche B-3 (the “Tranche B-3 Facility”) and a new Term Loan B facility Tranche B-4 (the “Tranche B-4 Facility”), respectively, and (ii) reduced the Applicable Rate from 2.75% to 2.50% in the case of Eurodollar Rate loans and reduced the Applicable Rate from 1.75% to 1.50% in the case of Base Rate Loans.

On March 29, 2018, the Company entered into a Third Repricing Facilities Amendment to the Amended and Restated Credit Agreement (the “Third Repricing Facilities Amendment”, and together with the Second Repricing Facilities Amendment, the “Repricing Facilities Amendments”). The Third Repricing Facilities Amendment replaced the existing revolving credit facility and Term Loan A facility (“TLA Facility”) with a new revolving credit facility and TLA Facility, respectively. The Company’s line of credit on its revolving credit facility remains at $500.0 million and the Third Repricing Facility Amendment reduced the size of the TLA Facility from $400.0 million to $380.0 million to reflect the then current outstanding principal. The Third Repricing Facilities Amendment reduced the Applicable Rate by 25 basis points for the revolving credit facility and the TLA Facility by amending the definition of “Applicable Rate.”

In connection with the Repricing Facilities Amendments, the Company recorded a debt extinguishment charge of $0.9 million, including the discount and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the condensed consolidated statements of income.

On February 6, 2019, the Company entered into the Eleventh Amendment (the “Eleventh Amendment”) to the Amended and Restated Credit Agreement. The Eleventh Amendment, among other things, amended the definition of “Consolidated EBITDA” to remove the cap on non-cash charges, losses and expenses related to the impairment of goodwill, which in turn provided increased flexibility to the Company in terms of the Company’s financial covenants.

On February 27, 2019, the Company entered into the Twelfth Amendment (the “Twelfth Amendment”) to the Amended and Restated Credit Agreement. The Twelfth Amendment, among other things, modified certain definitions, including “Consolidated EBITDA”, and increased our permitted Maximum Consolidated Leverage Ratio, thereby providing increased flexibility to the Company in terms of the Company’s financial covenants.

The Company had $422.4 million of availability under the revolving line of credit and had standby letters of credit outstanding of $12.6 million related to security for the payment of claims required by its workers’ compensation insurance program at June 30, 2019. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $4.8 million for September 30, 2019 to December 31, 2019, $7.1 million for March 31, 2020 to December 31, 2020, and $9.5 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. The Company is required to repay the Tranche B-3 Facility in equal quarterly installments of $1.2 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-3 Facility due on February 11, 2022. The Company is required to repay the Tranche B-4 Facility in equal quarterly installments of approximately $2.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-4 Facility due on February 16, 2023. On April 17, 2018, the Company made an additional payment of $15.0 million, including $5.1 million on the Tranche B-3 Facility and $9.9 million on the Tranche B-4 Facility.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $50.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.50% for Eurodollar Rate Loans (as defined in the

Amended and Restated Credit Agreement) and 1.50% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at June 30, 2019. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.00%. At June 30, 2019, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.50%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. At June 30, 2019, the Company was in compliance with such covenants.

Senior Notes

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

The indentures governing the 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

Equity-Based Compensation

6 Months Ended

Jun. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

10.	Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At June 30, 2019, a maximum of 8,200,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 2,855,613 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the most recent trading date prior to the date of grant.

The Company recognized $4.2 million and $7.1 million in equity-based compensation expense for the three months ended June 30, 2019 and 2018, respectively, and $10.3 million and $14.0 million for the six months ended June 30, 2019 and 2018, respectively. At June 30, 2019, there was $42.1 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.3 years.

At June 30, 2019, there were no warrants outstanding and exercisable. The Company recognized a deferred income tax benefit of $1.1 million and $1.9 million for the three months ended June 30, 2019 and 2018, respectively, related to equity-based compensation expense. The Company recognized a deferred income tax benefit of $2.8 million and $3.8 million for the six months ended June 30, 2019 and 2018, respectively, related to equity-based compensation expense.

Stock Options

Stock option activity during 2018 and 2019 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2018		974,566		$	47.89		7.46	$	3,802
Options granted		374,700			37.54		9.21		246
Options exercised		(20,989	)		17.83	N/A			383
Options cancelled		(128,737	)		50.83	N/A		N/A
Options outstanding at December 31, 2018		1,199,540			44.64		7.26		2,717
Options granted		566,800			28.25		9.69		1,196
Options exercised		(42,545	)		20.55	N/A			457
Options cancelled		(214,423	)		42.49	N/A		N/A
Options outstanding at June 30, 2019		1,509,372		$	39.44		7.98	$	1,855
Options exercisable at December 31, 2018		534,164		$	44.98		5.73	$	2,386
Options exercisable at June 30, 2019		571,267		$	47.60		6.21	$	718

Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2019 and year ended December 31, 2018:

	June 30, 2019			December 31, 2018
Weighted average grant-date fair value of options	$	10.45		$	13.67
Risk-free interest rate		2.4	%		2.2	%
Expected volatility		38	%		37	%
Expected life (in years)		5.0			5.1

The Company’s estimate of expected volatility for stock options is based upon the volatility of our stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U.S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Other Stock-Based Awards

Restricted stock activity during 2018 and 2019 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2018		809,868		$	50.19
Granted		480,137			36.84
Cancelled		(88,989	)		47.57
Vested		(395,959	)		50.41
Unvested at December 31, 2018		805,057		$	42.40
Granted		626,279			28.47
Cancelled		(289,914	)		32.35
Vested		(244,667	)		46.85
Unvested at June 30, 2019		896,755		$	34.71

Restricted stock unit activity during 2018 and 2019 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2018		360,909		$	50.04
Granted		285,358			42.26
Cancelled		(89,173	)		55.44
Vested		(72,983	)		49.64
Unvested at December 31, 2018		484,111		$	44.52
Granted		168,835			36.01
Cancelled		(267,161	)		45.20
Vested		—			—
Unvested at June 30, 2019		385,785		$	40.32

Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date.

Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets and Company performance compared to peers. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the two- or three-year period covered by the awards. The performance condition for the restricted stock units is based on the Company’s achievement of annually established targets for diluted earnings per share. Additionally, the number of shares issuable pursuant to restricted stock units granted during 2019 and 2018 are subject to adjustment based on the Company’s three-year annualized total stockholder return relative to a peer group consisting of S&P 1500 companies within the Healthcare Providers & Services 6 digit GICS industry group and selected other companies deemed to be peers. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of the targeted units based on the Company’s actual performance compared to the targets and, for 2019 and 2018 awards, performance compared to peers.

The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions.

Derivatives

6 Months Ended

Jun. 30, 2019

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivatives

12.	Derivatives

The Company entered into foreign currency forward contracts during the three and six months ended June 30, 2019 and 2018 in connection with certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between U.S. Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers.

In May 2016, the Company entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £449.3 million. During the term of the swap agreements, the Company will receive semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company will make semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements result in £24.7 million of annual cash flows from the Company’s U.K. business being converted to $35.8 million (at a 1.45 exchange rate).

The Company has designated the cross currency swap agreements and forward contracts entered into during 2018 and the six months ended June 30, 2019 as qualifying hedging instruments and is accounting for these as net investment hedges. The fair value of these derivatives at June 30, 2019 and December 31, 2018 of $73.0 million and $60.5 million, respectively, are recorded as derivative instrument assets on the condensed consolidated balance sheets. The gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swap derivatives are included in operating activities in the condensed consolidated statements of cash flows.

Fair Value Measurements

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

13.	Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, other long-term debt and derivative instruments at June 30, 2019 and December 31, 2018 were as follows (in thousands):

	Carrying Amount				Fair Value
	June 30, 2019		December 31, 2018		June 30, 2019		December 31, 2018
Amended and Restated Senior Credit Facility	$	1,766,191	$	1,715,338	$	1,766,191	$	1,715,338
6.125% Senior Notes due 2021	$	148,951	$	148,657	$	148,951	$	147,542
5.125% Senior Notes due 2022	$	297,348	$	296,946	$	298,835	$	283,583
5.625% Senior Notes due 2023	$	644,019	$	643,289	$	645,484	$	609,516
6.500% Senior Notes due 2024	$	383,858	$	383,304	$	400,172	$	369,888
Other long-term debt	$	5,396	$	5,953	$	5,396	$	5,953
Derivative instrument assets	$	72,965	$	60,524	$	72,965	$	60,524

The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes and other long-term debt were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair values of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

14.	Commitments and Contingencies

Professional and General Liability

A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary. The Company is self-insured for professional liability claims up to $3.0 million per claim and has obtained reinsurance coverage from a third party to cover claims in excess of the retention limit. The reinsurance policy has a coverage limit of $75.0 million in the aggregate. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place.

Legal Proceedings

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the federal False Claims Act permits private parties to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988, which is pending in the United States District Court for the Middle District of Tennessee. The complaint purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. At this time, we are not able to quantify any potential liability in connection with this litigation because the case is in its early stages.

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Davydov v. Joey A. Jacobs, et al., Case No. 3:19-cv-00167, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Beard v. Jacobs, et al., Case No. 3:19-cv-0441, which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated and ordered stayed pending a ruling on the motion to dismiss that was filed in the St. Clair County v. Acadia Healthcare case described above. At this time, we are not able to quantify any potential liability in connection with this litigation because the cases are in their early stages.

During the second quarter of 2019, the Company reached a settlement with the U.S. Attorney’s Office for the Southern District of West Virginia relating to the manner in which seven of our comprehensive treatment centers in West Virginia had historically billed lab claims to the West Virginia Medicaid Program. The Company paid the government $17.0 million during the three months ended June 30, 2019 and entered into a corporate integrity agreement with the Office of Inspector General imposing customary compliance obligations on our subsidiary, CRC Health.

In the fall of 2017, the Office of Inspector General issued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the Office of Inspector General issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company

is cooperating with the government’s investigation but is not able to quantify any potential liability in connection with these investigations.

Noncontrolling Interests

6 Months Ended

Jun. 30, 2019

Noncontrolling Interest [Abstract]

Noncontrolling Interests

15.	Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At June 30, 2019, the Company operated five facilities and owns between 60% and 85% of the equity interests, and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions, and the Company consolidates the operations of each facility based on its equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the condensed consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at December 31, 2018	$	28,806
Acquisition of redeemable noncontrolling interests		3,300
Net income attributable to noncontrolling interests		101
Balance at June 30, 2019	$	32,207

Other Current Assets

6 Months Ended

Jun. 30, 2019

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

16.	Other Current Assets

Other current assets consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Prepaid expenses	$	19,963	$	30,802
Other receivables		19,005		19,205
Cost report receivable		12,594		10,340
Workers’ compensation deposits – current portion		10,000		10,000
Income taxes receivable		9,727		2,380
Inventory		6,076		5,055
Insurance receivable – current portion		2,049		2,049
Other		2,050		1,989
Other current assets	$	81,464	$	81,820

Other Accrued Liabilities

6 Months Ended

Jun. 30, 2019

Other Liabilities Disclosure [Abstract]

Other Accrued Liabilities

17.	Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Accrued expenses	$	39,824	$	44,938
Unearned income		35,235		32,154
Accrued interest		33,417		32,838
Income taxes payable		8,047		3,041
Finance lease liabilities		7,095		445
Accrued property taxes		6,077		4,136
Insurance liability – current portion		4,956		4,956
Accrued legal settlements		—		22,076
Other		3,468		6,642
Other accrued liabilities	$	138,119	$	151,226

Segment Information

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Segment Information

18.	Segment Information

The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its U.S. Facilities and its U.K. Facilities separately to assess performance and make decisions, the Company’s operating segments include our U.S. Facilities and U.K. Facilities. At June 30, 2019, the U.S. Facilities segment included 225 behavioral healthcare facilities with approximately 9,400 beds in 40 states and Puerto Rico, and the U.K. Facilities segment included 370 behavioral healthcare facilities with approximately 8,800 beds in the U.K.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Revenue:
U.S. Facilities	$	509,813		$	481,470		$	997,773		$	943,875
U.K. Facilities		279,549			284,268			552,206			564,104
Corporate and Other		—			—			—			—
	$	789,362		$	765,738		$	1,549,979		$	1,507,979
Segment EBITDA (1):
U.S. Facilities	$	135,396		$	130,002		$	254,404		$	247,126
U.K. Facilities		45,835			54,194			85,891			105,346
Corporate and Other		(22,345	)		(19,182	)		(45,406	)		(41,727	)
	$	158,886		$	165,014		$	294,889		$	310,745

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Segment EBITDA (1)	$	158,886		$	165,014		$	294,889		$	310,745
Less:
Equity-based compensation expense		(4,182	)		(7,129	)		(10,283	)		(14,048	)
Transaction-related expenses		(5,212	)		(2,887	)		(9,533	)		(7,655	)
Debt extinguishment costs		—			—			—			(940	)
Interest expense, net		(48,610	)		(45,812	)		(96,740	)		(91,055	)
Depreciation and amortization		(41,077	)		(39,928	)		(81,657	)		(79,701	)
Income before income taxes	$	59,805		$	69,258		$	96,676		$	117,346

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2019	$	2,044,837	$	351,575		$	—	$	2,396,412
Increase from 2019 acquisitions		36,528		—			—		36,528
Increase from contribution of redeemable noncontrolling interests		3,300		—			—		3,300
Foreign currency translation loss		—		(1,215	)		—		(1,215	)
Balance at June 30, 2019	$	2,084,665	$	350,360		$	—	$	2,435,025

	June 30, 2019		December 31, 2018
Assets (2):
U.S. Facilities	$	3,995,903	$	3,779,040
U.K. Facilities		2,543,030		2,175,809
Corporate and Other		251,485		217,655
	$	6,790,418	$	6,172,504

(1)

Segment EBITDA is defined as income before provision for income taxes, equity-based compensation expense, transaction-related expenses, debt extinguishment costs, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(2)

Assets include property and equipment for the U.S. Facilities of $1.4 billion, U.K. Facilities of $1.7 billion and corporate and other of $49.3 million at June 30, 2019. Assets include property and equipment for the U.S. Facilities of $1.4 billion, U.K. Facilities of $1.7 billion and corporate and other of $44.9 million at December 31, 2018.

Accumulated Other Comprehensive Loss

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Accumulated Other Comprehensive Loss

19.	Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments		Pension Plan			Total
Balance at December 31, 2018	$	(504,528	)	$	43,966	$	(1,815	)	$	(462,377	)
Foreign currency translation (loss) gain		(6,143	)		—		6			(6,137	)
Gain on derivative instruments, net of tax of $5.7 million		—			8,897		—			8,897
Balance at June 30, 2019	$	(510,671	)	$	52,863	$	(1,809	)	$	(459,617	)

Financial Information for the Company and Its Subsidiaries

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Financial Information for the Company and Its Subsidiaries

20.	Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries at June 30, 2019 and December 31, 2018, and for the three and six months ended June 30, 2019 and 2018. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

June 30, 2019

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	30,264	$	13,277	$	—		$	43,541
Accounts receivable, net		—		278,255		68,234		—			346,489
Other current assets		—		67,790		13,674		—			81,464
Total current assets		—		376,309		95,185		—			471,494
Property and equipment, net		—		1,296,263		1,867,813		—			3,164,076
Goodwill		—		1,991,905		443,120		—			2,435,025
Intangible assets, net		—		58,355		31,258		—			89,613
Deferred tax assets		2,038		—		3,404		(2,038	)		3,404
Derivative instrument assets		72,965		—		—		—			72,965
Investment in subsidiaries		5,374,016		—		—		(5,374,016	)		—
Operating lease right-of-use assets		—		95,880		395,671		—			491,551
Other assets		252,507		53,419		5,502		(249,138	)		62,290
Total assets	$	5,701,526	$	3,872,131	$	2,841,953	$	(5,625,192	)	$	6,790,418

Current liabilities:
Current portion of long-term debt	$	38,895	$	—	$	—	$	—		$	38,895
Accounts payable		—		81,388		34,263		—			115,651
Accrued salaries and benefits		—		80,563		29,882		—			110,445
Current portion of operating lease liabilities		—		16,862		10,716		—			27,578
Other accrued liabilities		33,417		21,875		82,827		—			138,119
Total current liabilities		72,312		200,688		157,688		—			430,688
Long-term debt		3,206,868		—		249,138		(249,138	)		3,206,868
Deferred tax liabilities		—		36,334		48,800		(2,038	)		83,096
Operating lease liabilities		—		84,286		406,617		—			490,903
Other liabilities		—		106,832		17,478		—			124,310
Total liabilities		3,279,180		428,140		879,721		(251,176	)		4,335,865
Redeemable noncontrolling interests		—		—		32,207		—			32,207
Total equity		2,422,346		3,443,991		1,930,025		(5,374,016	)		2,422,346
Total liabilities and equity	$	5,701,526	$	3,872,131	$	2,841,953	$	(5,625,192	)	$	6,790,418

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2018

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	32,471	$	18,039	$	—		$	50,510
Accounts receivable, net		—		248,218		69,869		—			318,087
Other current assets		—		60,160		21,660		—			81,820
Total current assets		—		340,849		109,568		—			450,417
Property and equipment, net		—		1,219,803		1,887,963		—			3,107,766
Goodwill		—		1,936,057		460,355		—			2,396,412
Intangible assets, net		—		56,611		32,379		—			88,990
Deferred tax assets – noncurrent		1,841		—		3,468		(1,841	)		3,468
Derivative instruments		60,524		—		—		—			60,524
Investment in subsidiaries		5,190,771		—		—		(5,190,771	)		—
Other assets		306,495		52,824		9,548		(303,940	)		64,927
Total assets	$	5,559,631	$	3,606,144	$	2,503,281	$	(5,496,552	)	$	6,172,504
Current liabilities:
Current portion of long-term debt	$	34,112	$	—	$	—	$	—		$	34,112
Accounts payable		—		79,463		38,277		—			117,740
Accrued salaries and benefits		—		84,150		29,149		—			113,299
Other accrued liabilities		32,837		42,062		76,327		—			151,226
Total current liabilities		66,949		205,675		143,753		—			416,377
Long-term debt		3,159,375		—		303,940		(303,940	)		3,159,375
Deferred tax liabilities – noncurrent		—		31,874		50,339		(1,841	)		80,372
Other liabilities		—		107,866		46,401		—			154,267
Total liabilities		3,226,324		345,415		544,433		(305,781	)		3,810,391
Redeemable noncontrolling interests		—		—		28,806		—			28,806
Total equity		2,333,307		3,260,729		1,930,042		(5,190,771	)		2,333,307
Total liabilities and equity	$	5,559,631	$	3,606,144	$	2,503,281	$	(5,496,552	)	$	6,172,504

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended June 30, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	480,250	$	309,112		$	—		$	789,362
Salaries, wages and benefits		4,182			254,656		171,381			—			430,219
Professional fees		—			26,340		32,089			—			58,429
Supplies		—			20,078		10,836			—			30,914
Rents and leases		—			8,716		11,703			—			20,419
Other operating expenses		—			61,519		33,158			—			94,677
Depreciation and amortization		—			20,017		21,060			—			41,077
Interest expense, net		20,138			23,486		4,986			—			48,610
Transaction-related expenses		—			4,578		634			—			5,212
Total expenses		24,320			419,390		285,847			—			729,557
(Loss) income before income taxes		(24,320	)		60,860		23,265			—			59,805
Equity in earnings of subsidiaries		65,884			—		—			(65,884	)		—
(Benefit from) provision for income taxes		(6,637	)		25,298		(7,057	)		—			11,604
Net income (loss)		48,201			35,562		30,322			(65,884	)		48,201
Net income attributable to noncontrolling interests		—			—		(61	)		—			(61	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	48,201		$	35,562	$	30,261		$	(65,884	)	$	48,140
Other comprehensive income:
Foreign currency translation loss		—			—		(50,618	)		—			(50,618	)
Gain on derivative instruments		17,587			—		—			—			17,587
Other comprehensive income (loss)		17,587			—		(50,618	)		—			(33,031	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	65,788		$	35,562	$	(20,357	)	$	(65,884	)	$	15,109

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	453,782	$	311,956		$	—		$	765,738
Salaries, wages and benefits		7,129			239,999		169,613			—			416,741
Professional fees		—			24,677		28,784			—			53,461
Supplies		—			19,292		10,841			—			30,133
Rents and leases		—			8,311		11,925			—			20,236
Other operating expenses		—			55,258		32,024			—			87,282
Depreciation and amortization		—			18,611		21,317			—			39,928
Interest expense, net		15,465			23,602		6,745			—			45,812
Transaction-related expenses		—			2,671		216			—			2,887
Total expenses		22,594			392,421		281,465			—			696,480
(Loss) income before income taxes		(22,594	)		61,361		30,491			—			69,258
Equity in earnings of subsidiaries		75,752			—		—			(75,752	)		—
(Benefit from) provision for income taxes		(5,732	)		11,442		4,658			—			10,368
Net income (loss)		58,890			49,919		25,833			(75,752	)		58,890
Net loss attributable to noncontrolling interests		—			—		(54	)		—			(54	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	58,890		$	49,919	$	25,779		$	(75,752	)	$	58,836
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(143,599	)		—			(143,599	)
Gain on derivative instruments		29,107			—		—			—			29,107
Other comprehensive income (loss)		29,107			—		(143,599	)		—			(114,492	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	87,997		$	49,919	$	(117,820	)	$	(75,752	)	$	(55,656	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Six Months Ended June 30, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	940,068	$	609,911		$	—		$	1,549,979
Salaries, wages and benefits		10,283			509,598		339,917			—			859,798
Professional fees		—			51,708		63,728			—			115,436
Supplies		—			39,462		21,409			—			60,871
Rents and leases		—			17,119		23,607			—			40,726
Other operating expenses		—			120,909		67,633			—			188,542
Depreciation and amortization		—			39,622		42,035			—			81,657
Interest expense, net		39,716			46,504		10,520			—			96,740
Transaction-related expenses		—			7,796		1,737			—			9,533
Total expenses		49,999			832,718		570,586			—			1,453,303
(Loss) income before income taxes		(49,999	)		107,350		39,325			—			96,676
Equity in earnings of subsidiaries		114,041			—		—			(114,041	)		—
(Benefit from) provision for income taxes		(13,670	)		42,363		(9,729	)		—			18,964
Net income (loss)		77,712			64,987		49,054			(114,041	)		77,712
Net gain attributable to noncontrolling interests		—			—		(101	)		—			(101	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	77,712		$	64,987	$	48,953		$	(114,041	)	$	77,611
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(6,137	)		—			(6,137	)
Gain on derivative instruments		8,897			—		—			—			8,897
Other comprehensive income (loss)		8,897			—		(6,137	)		—			2,760
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	86,609		$	64,987	$	42,816		$	(114,041	)	$	80,371

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Six Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	889,407	$	618,572		$	—			1,507,979
Salaries, wages and benefits		14,048			479,051		335,170			—			828,269
Professional fees		—			48,948		58,531			—			107,479
Supplies		—			38,004		21,493			—			59,497
Rents and leases		—			16,550		23,974			—			40,524
Other operating expenses		—			111,428		64,085			—			175,513
Depreciation and amortization		—			36,783		42,918			—			79,701
Interest expense, net		30,082			47,186		13,787			—			91,055
Debt extinguishment costs		940			—		—			—			940
Transaction-related expenses		—			6,680		975			—			7,655
Total expenses		45,070			784,630		560,933			—			1,390,633
(Loss) income before income taxes		(45,070	)		104,777		57,639			—			117,346
Equity in earnings of subsidiaries		143,350			—		—			(143,350	)		—
(Benefit from) provision for income taxes		(11,484	)		11,319		7,747			—			7,582
Net income (loss)		109,764			93,458		49,892			(143,350	)		109,764
Net income attributable to noncontrolling interests		—			—		(109	)		—			(109	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	109,764		$	93,458	$	49,783		$	(143,350	)	$	109,655
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(50,819	)		—			(50,819	)
Gain on derivative instruments		9,054			—		—			—			9,054
Other comprehensive income (loss)		9,054			—		(50,819	)		—			(41,765	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	118,818		$	93,458	$	(1,036	)	$	(143,350	)	$	67,890

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	77,712		$	64,987		$	49,054		$	(114,041	)	$	77,712
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(114,041	)		—			—			114,041			—
Depreciation and amortization		—			39,622			42,035			—			81,657
Amortization of debt issuance costs		5,887			—			—			—			5,887
Equity-based compensation expense		10,283			—			—			—			10,283
Deferred income taxes		(198	)		(73	)		66			—			(205	)
Other		2,126			321			(52	)		—			2,395
Change in operating assets and liabilities:
Accounts receivable, net		—			(24,767	)		(2,902	)		—			(27,669	)
Other current assets		—			(11,029	)		438			—			(10,591	)
Other assets		3,097			(714	)		1,375			(3,097	)		661
Accounts payable and other accrued liabilities		—			942			(12,002	)		—			(11,060	)
Accrued salaries and benefits		—			(4,628	)		1,396			—			(3,232	)
Other liabilities		—			5,558			(2,710	)		—			2,848
Net cash (used in) provided by operating activities		(15,134	)		70,219			76,698			(3,097	)		128,686
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(44,900	)		—			—			(44,900	)
Cash paid for capital expenditures		—			(93,952	)		(45,176	)		—			(139,128	)
Cash paid for real estate acquisitions		—			(4,448	)		—			—			(4,448	)
Other		—			6,402			4,092			—			10,494
Net cash used in investing activities		—			(136,898	)		(41,084	)		—			(177,982	)
Financing activities:
Borrowings on revolving credit facility		76,573			—			—			—			76,573
Principal payments on revolving credit facility		(11,573	)		—			—			—			(11,573	)
Principal payments on long-term debt		(16,492	)		—			(3,097	)		3,097			(16,492	)
Common stock withheld for minimum statutory taxes, net		(1,615	)		—			—			—			(1,615	)
Other		(2,375	)		(889	)		(1,081	)		—			(4,345	)
Cash (used in) provided by intercompany activity		(29,384	)		65,361			(35,977	)		—			—
Net provided by (used in) in financing activities		15,134			64,472			(40,155	)		3,097			42,548
Effect of exchange rate changes on cash		—			—			(221	)		—			(221	)
Net decrease in cash and cash equivalents		—			(2,207	)		(4,762	)		—			(6,969	)
Cash and cash equivalents at beginning of the period		—			32,471			18,039			—			50,510
Cash and cash equivalents at end of the period	$	—		$	30,264		$	13,277		$	—		$	43,541

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	109,764		$	93,458		$	49,892		$	(143,350	)	$	109,764
Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities:
Equity in earnings of subsidiaries		(143,350	)		—			—			143,350			—
Depreciation and amortization		—			36,783			42,918			—			79,701
Amortization of debt issuance costs		5,326			—			(202	)		—			5,124
Equity-based compensation expense		14,048			—			—			—			14,048
Deferred income taxes		1,438			(5,843	)		427			—			(3,978	)
Debt extinguishment costs		940			—			—			—			940
Other		240			1,149			(349	)		—			1,040
Change in operating assets and liabilities:
Accounts receivable, net		—			(23,064	)		(3,040	)		—			(26,104	)
Other current assets		—			12,197			(2,244	)		—			9,953
Other assets		4,514			2,689			72			(4,514	)		2,761
Accounts payable and other accrued liabilities		—			27,859			(6,793	)		—			21,066
Accrued salaries and benefits		—			4,487			(123	)		—			4,364
Other liabilities		—			3,002			(3,795	)		—			(793	)
Net cash provided by (used in) continuing operating activities		(7,080	)		152,717			76,763			(4,514	)		217,886
Net cash used in discontinued operating activities		—			(572	)		—			—			(572	)
Net cash provided by (used in) operating activities		(7,080	)		152,145			76,763			(4,514	)		217,314
Investing activities:
Cash paid for capital expenditures		—			(97,186	)		(64,369	)		—			(161,555	)
Cash paid for real estate acquisitions		—			(8,857	)		—			—			(8,857	)
Other		—			(5,759	)		2,422			—			(3,337	)
Net cash used in investing activities		—			(111,802	)		(61,947	)		—			(173,749	)
Financing activities:
Principal payments on long-term debt		(23,246	)		(169	)		(4,345	)		4,514			(23,246	)
Common stock withheld for minimum statutory taxes, net		(2,134	)		—			—			—			(2,134	)
Other		(1,742	)		(1,924	)		(1,506	)		—			(5,172	)
Cash provided by (used in) intercompany activity		34,202			(25,131	)		(9,071	)		—			—
Net (used in) provided by in financing activities		7,080			(27,224	)		(14,922	)		4,514			(30,552	)
Effect of exchange rate changes on cash		—			—			(840	)		—			(840	)
Net increase (decrease) in cash and cash equivalents		—			13,119			(946	)		—			12,173
Cash and cash equivalents at beginning of the period		—			46,860			20,430			—			67,290
Cash and cash equivalents at end of the period	$	—		$	59,979		$	19,484		$	—		$	79,463

Revenue (Tables)

6 Months Ended

Jun. 30, 2019

Summary of the Activity in Unearned Revenue in the U.K. Facilities

A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands):

Balance at December 31, 2018	$	31,239
Payments received		87,690
Revenue recognized		(83,456	)
Foreign currency translation loss		(747	)
Balance at June 30, 2019	$	34,726

U.S. Facilities [Member]

Schedule of Revenue Attributed to Each Category

The table below presents total U.S. revenue attributed to each category (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Acute inpatient psychiatric facilities	$	229,128	$	203,535	$	445,725	$	399,426
Specialty treatment facilities		201,269		192,894		394,304		377,429
Residential treatment centers		74,084		74,133		147,308		145,690
Outpatient community-based facilities		5,332		10,908		10,436		21,330
Revenue	$	509,813	$	481,470	$	997,773	$	943,875

Schedule of Revenue and Percentage Generated by Each Payor Type

The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2019					2018					2019					2018
	Amount		%			Amount		%			Amount		%			Amount		%
Commercial	$	146,917		28.8	%	$	147,279		30.6	%	$	286,344		28.7	%	$	284,898		30.2	%
Medicare		73,505		14.4	%		69,343		14.4	%		146,121		14.6	%		136,557		14.5	%
Medicaid		255,070		50.0	%		225,732		46.9	%		494,261		49.5	%		439,068		46.5	%
Self-Pay		29,624		5.8	%		33,379		6.9	%		61,356		6.2	%		70,286		7.4	%
Other		4,697		1.0	%		5,737		1.2	%		9,691		1.0	%		13,066		1.4	%
Revenue	$	509,813		100.0	%	$	481,470		100.0	%	$	997,773		100.0	%	$	943,875		100.0	%

U.K. Facilities [Member]

Schedule of Revenue Attributed to Each Category

The table below presents total U.K. revenue attributed to each category (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Healthcare facilities	$	155,553	$	158,894	$	307,261	$	313,509
Education and Children’s Services		46,142		48,065		92,264		96,150
Adult Care facilities		77,854		77,309		152,681		154,445
Revenue	$	279,549	$	284,268	$	552,206	$	564,104

Schedule of Revenue and Percentage Generated by Each Payor Type

The following table presents revenue by payor type and as a percentage of revenue in our U.K. Facilities (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2019					2018					2019					2018
	Amount		%			Amount		%			Amount		%			Amount		%
U.K. public funded sources	$	252,332		90.3	%	$	256,881		90.4	%	$	497,745		90.1	%	$	510,175		90.4	%
Self-Pay		26,651		9.5	%		27,272		9.6	%		53,465		9.7	%		52,340		9.3	%
Other		566		0.2	%		115		0.0	%		996		0.2	%		1,589		0.3	%
Revenue	$	279,549		100.0	%	$	284,268		100.0	%	$	552,206		100.0	%	$	564,104		100.0	%

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2019 and 2018 (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$	48,140	$	58,836	$	77,611	$	109,655
Denominator:
Weighted average shares outstanding for basic earnings per share		87,618		87,303		87,562		87,205
Effect of dilutive instruments		219		164		208		146
Shares used in computing diluted earnings per common share		87,837		87,467		87,770		87,351
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$	0.55	$	0.67	$	0.89	$	1.26
Diluted	$	0.55	$	0.67	$	0.88	$	1.26

Acquisitions (Tables)

6 Months Ended

Jun. 30, 2019

Business Combinations [Abstract]

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Termination, restructuring and strategic review costs	$	4,792	$	2,009	$	8,317	$	5,401
Legal, accounting and other acquisition-related costs		420		878		1,216		2,254
	$	5,212	$	2,887	$	9,533	$	7,655

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2019

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following at June 30, 2019 and December 31, 2018 (in thousands):

	June 30, 2019			December 31, 2018
Land	$	446,795		$	430,771
Building and improvements		2,591,815			2,423,594
Equipment		469,107			444,538
Construction in progress		199,836			294,848
		3,707,553			3,593,751
Less: accumulated depreciation		(543,477	)		(485,985	)
Property and equipment, net	$	3,164,076		$	3,107,766

Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following at June 30, 2019 and December 31, 2018 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	June 30, 2019		December 31, 2018		June 30, 2019			December 31, 2018
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(2,100	)
Non-compete agreements		1,147		1,147		(1,147	)		(1,147	)
		3,247		3,247		(3,247	)		(3,247	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,599		12,343		—			—
Trade names		60,039		60,109		—			—
Certificates of need		16,975		16,538		—			—
		89,613		88,990		—			—
Total	$	92,860	$	92,237	$	(3,247	)	$	(3,247	)

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Schedule Of Leases On Condensed Consolidated Balance Sheet

At June 30, 2019, the Company recorded the following on the condensed consolidated balance sheet (in thousands):

Right-of-Use Assets	Balance Sheet Classification	June 30, 2019
Finance lease right-of-use assets	Property and equipment, net	$	44,981
Operating lease right-of-use assets	Operating lease right-of-use assets		491,551
Total		$	536,532

Lease Liabilities	Balance Sheet Classification	June 30, 2019
Current:
Finance lease liabilities	Other accrued liabilities	$	7,095
Operating lease liabilities	Current portion of operating lease liabilities		27,578
Noncurrent:
Finance lease liabilities	Other liabilities		44,088
Operating lease liabilities	Operating lease liabilities		490,903
Total		$	569,664

Schedule of Weighted-average Remaining Lease Terms and Discount Rates

Weighted-average remaining lease terms and discount rates at June 30, 2019 were as follows:


Weighted-average remaining lease term (in years):
Finance	7.2
Operating	19.7

Weighted-average discount rate:
Finance		6.4	%
Operating		6.4	%

Schedule of Lease Cost

The Company recorded the following lease costs for the three and six months ended June 30, 2019 (in thousands):

	Three Months Ended June 30, 2019		Six Months Ended June 30, 2019
Finance lease costs:
Depreciation of leased assets		1,136		2,259
Interest of lease liabilities		999		1,996
Total finance lease costs	$	2,135	$	4,255

Operating lease costs		16,237		32,766
Variable lease costs		1,044		1,930
Short term lease costs		1,483		2,930
Other lease costs		1,655		3,100
Total rents and leases	$	20,419	$	40,726

Total lease costs	$	22,554	$	44,981

Schedule of Undiscounted Cash Flows for Finance and Operating Leases

Undiscounted cash flows for finance and operating leases recorded on the condensed consolidated balance sheet were as follows at June 30, 2019 (in thousands):

	Finance Leases		Operating Leases
For the six months ending December 31, 2019	$	4,137	$	30,201
2020		6,938		58,325
2021		35,101		54,702
2022		2,193		50,007
2023		1,063		46,511
Thereafter		26,094		708,139
Total minimum lease payments		75,526		947,885
Less: amount of lease payments representing interest		24,343		429,404
Present value of future minimum lease payments		51,183		518,481
Less: Current portion of lease liabilities		7,095		27,578
Noncurrent lease liabilities	$	44,088	$	490,903

Schedule of Supplemental Data

Supplemental data for the six months ended June 30, 2019 was as follows (in thousands):

	Six Months Ended June 30,
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	31,212
Operating cash flows for finance leases	$	1,996
Financing cash flows for finance leases	$	1,684

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	10,674
Finance leases	$	1,774

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans	$	356,250		$	365,750
Senior Secured Term B Loans		1,365,920			1,372,912
Senior Secured Revolving Line of Credit		65,000			—
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
Other long-term debt		5,396			5,953
Less: unamortized debt issuance costs, discount and premium		(36,803	)		(41,128	)
		3,245,763			3,193,487
Less: current portion		(38,895	)		(34,112	)
Long-term debt	$	3,206,868		$	3,159,375

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Equity-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Activity

Stock option activity during 2018 and 2019 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2018		974,566		$	47.89		7.46	$	3,802
Options granted		374,700			37.54		9.21		246
Options exercised		(20,989	)		17.83	N/A			383
Options cancelled		(128,737	)		50.83	N/A		N/A
Options outstanding at December 31, 2018		1,199,540			44.64		7.26		2,717
Options granted		566,800			28.25		9.69		1,196
Options exercised		(42,545	)		20.55	N/A			457
Options cancelled		(214,423	)		42.49	N/A		N/A
Options outstanding at June 30, 2019		1,509,372		$	39.44		7.98	$	1,855
Options exercisable at December 31, 2018		534,164		$	44.98		5.73	$	2,386
Options exercisable at June 30, 2019		571,267		$	47.60		6.21	$	718

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2019 and year ended December 31, 2018:

	June 30, 2019			December 31, 2018
Weighted average grant-date fair value of options	$	10.45		$	13.67
Risk-free interest rate		2.4	%		2.2	%
Expected volatility		38	%		37	%
Expected life (in years)		5.0			5.1

Restricted Stock Activity

Restricted stock activity during 2018 and 2019 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2018		809,868		$	50.19
Granted		480,137			36.84
Cancelled		(88,989	)		47.57
Vested		(395,959	)		50.41
Unvested at December 31, 2018		805,057		$	42.40
Granted		626,279			28.47
Cancelled		(289,914	)		32.35
Vested		(244,667	)		46.85
Unvested at June 30, 2019		896,755		$	34.71

Restricted Stock Unit Activity

Restricted stock unit activity during 2018 and 2019 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2018		360,909		$	50.04
Granted		285,358			42.26
Cancelled		(89,173	)		55.44
Vested		(72,983	)		49.64
Unvested at December 31, 2018		484,111		$	44.52
Granted		168,835			36.01
Cancelled		(267,161	)		45.20
Vested		—			—
Unvested at June 30, 2019		385,785		$	40.32

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities

	Carrying Amount				Fair Value
	June 30, 2019		December 31, 2018		June 30, 2019		December 31, 2018
Amended and Restated Senior Credit Facility	$	1,766,191	$	1,715,338	$	1,766,191	$	1,715,338
6.125% Senior Notes due 2021	$	148,951	$	148,657	$	148,951	$	147,542
5.125% Senior Notes due 2022	$	297,348	$	296,946	$	298,835	$	283,583
5.625% Senior Notes due 2023	$	644,019	$	643,289	$	645,484	$	609,516
6.500% Senior Notes due 2024	$	383,858	$	383,304	$	400,172	$	369,888
Other long-term debt	$	5,396	$	5,953	$	5,396	$	5,953
Derivative instrument assets	$	72,965	$	60,524	$	72,965	$	60,524

Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2019

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

Other current assets consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Prepaid expenses	$	19,963	$	30,802
Other receivables		19,005		19,205
Cost report receivable		12,594		10,340
Workers’ compensation deposits – current portion		10,000		10,000
Income taxes receivable		9,727		2,380
Inventory		6,076		5,055
Insurance receivable – current portion		2,049		2,049
Other		2,050		1,989
Other current assets	$	81,464	$	81,820

Other Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2019

Other Liabilities Disclosure [Abstract]

Summary of Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Accrued expenses	$	39,824	$	44,938
Unearned income		35,235		32,154
Accrued interest		33,417		32,838
Income taxes payable		8,047		3,041
Finance lease liabilities		7,095		445
Accrued property taxes		6,077		4,136
Insurance liability – current portion		4,956		4,956
Accrued legal settlements		—		22,076
Other		3,468		6,642
Other accrued liabilities	$	138,119	$	151,226

Segment Information (Tables)

6 Months Ended

Jun. 30, 2019

Summary of Reconciliation of Segment EBITDA to Income before Income Taxes

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Revenue:
U.S. Facilities	$	509,813		$	481,470		$	997,773		$	943,875
U.K. Facilities		279,549			284,268			552,206			564,104
Corporate and Other		—			—			—			—
	$	789,362		$	765,738		$	1,549,979		$	1,507,979
Segment EBITDA (1):
U.S. Facilities	$	135,396		$	130,002		$	254,404		$	247,126
U.K. Facilities		45,835			54,194			85,891			105,346
Corporate and Other		(22,345	)		(19,182	)		(45,406	)		(41,727	)
	$	158,886		$	165,014		$	294,889		$	310,745

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Segment EBITDA (1)	$	158,886		$	165,014		$	294,889		$	310,745
Less:
Equity-based compensation expense		(4,182	)		(7,129	)		(10,283	)		(14,048	)
Transaction-related expenses		(5,212	)		(2,887	)		(9,533	)		(7,655	)
Debt extinguishment costs		—			—			—			(940	)
Interest expense, net		(48,610	)		(45,812	)		(96,740	)		(91,055	)
Depreciation and amortization		(41,077	)		(39,928	)		(81,657	)		(79,701	)
Income before income taxes	$	59,805		$	69,258		$	96,676		$	117,346

Summary of Assets by Operating Segment

	June 30, 2019		December 31, 2018
Assets (2):
U.S. Facilities	$	3,995,903	$	3,779,040
U.K. Facilities		2,543,030		2,175,809
Corporate and Other		251,485		217,655
	$	6,790,418	$	6,172,504

(1)

(2)

Goodwill [Member]

Summary of Assets by Operating Segment

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2019	$	2,044,837	$	351,575		$	—	$	2,396,412
Increase from 2019 acquisitions		36,528		—			—		36,528
Increase from contribution of redeemable noncontrolling interests		3,300		—			—		3,300
Foreign currency translation loss		—		(1,215	)		—		(1,215	)
Balance at June 30, 2019	$	2,084,665	$	350,360		$	—	$	2,435,025

Accumulated Other Comprehensive Loss (Tables)

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Components Of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments		Pension Plan			Total
Balance at December 31, 2018	$	(504,528	)	$	43,966	$	(1,815	)	$	(462,377	)
Foreign currency translation (loss) gain		(6,143	)		—		6			(6,137	)
Gain on derivative instruments, net of tax of $5.7 million		—			8,897		—			8,897
Balance at June 30, 2019	$	(510,671	)	$	52,863	$	(1,809	)	$	(459,617	)

Financial Information for the Company and Its Subsidiaries (Tables)

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Condensed Consolidating Balance Sheets

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

June 30, 2019

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	30,264	$	13,277	$	—		$	43,541
Accounts receivable, net		—		278,255		68,234		—			346,489
Other current assets		—		67,790		13,674		—			81,464
Total current assets		—		376,309		95,185		—			471,494
Property and equipment, net		—		1,296,263		1,867,813		—			3,164,076
Goodwill		—		1,991,905		443,120		—			2,435,025
Intangible assets, net		—		58,355		31,258		—			89,613
Deferred tax assets		2,038		—		3,404		(2,038	)		3,404
Derivative instrument assets		72,965		—		—		—			72,965
Investment in subsidiaries		5,374,016		—		—		(5,374,016	)		—
Operating lease right-of-use assets		—		95,880		395,671		—			491,551
Other assets		252,507		53,419		5,502		(249,138	)		62,290
Total assets	$	5,701,526	$	3,872,131	$	2,841,953	$	(5,625,192	)	$	6,790,418

Current liabilities:
Current portion of long-term debt	$	38,895	$	—	$	—	$	—		$	38,895
Accounts payable		—		81,388		34,263		—			115,651
Accrued salaries and benefits		—		80,563		29,882		—			110,445
Current portion of operating lease liabilities		—		16,862		10,716		—			27,578
Other accrued liabilities		33,417		21,875		82,827		—			138,119
Total current liabilities		72,312		200,688		157,688		—			430,688
Long-term debt		3,206,868		—		249,138		(249,138	)		3,206,868
Deferred tax liabilities		—		36,334		48,800		(2,038	)		83,096
Operating lease liabilities		—		84,286		406,617		—			490,903
Other liabilities		—		106,832		17,478		—			124,310
Total liabilities		3,279,180		428,140		879,721		(251,176	)		4,335,865
Redeemable noncontrolling interests		—		—		32,207		—			32,207
Total equity		2,422,346		3,443,991		1,930,025		(5,374,016	)		2,422,346
Total liabilities and equity	$	5,701,526	$	3,872,131	$	2,841,953	$	(5,625,192	)	$	6,790,418

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2018

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	32,471	$	18,039	$	—		$	50,510
Accounts receivable, net		—		248,218		69,869		—			318,087
Other current assets		—		60,160		21,660		—			81,820
Total current assets		—		340,849		109,568		—			450,417
Property and equipment, net		—		1,219,803		1,887,963		—			3,107,766
Goodwill		—		1,936,057		460,355		—			2,396,412
Intangible assets, net		—		56,611		32,379		—			88,990
Deferred tax assets – noncurrent		1,841		—		3,468		(1,841	)		3,468
Derivative instruments		60,524		—		—		—			60,524
Investment in subsidiaries		5,190,771		—		—		(5,190,771	)		—
Other assets		306,495		52,824		9,548		(303,940	)		64,927
Total assets	$	5,559,631	$	3,606,144	$	2,503,281	$	(5,496,552	)	$	6,172,504
Current liabilities:
Current portion of long-term debt	$	34,112	$	—	$	—	$	—		$	34,112
Accounts payable		—		79,463		38,277		—			117,740
Accrued salaries and benefits		—		84,150		29,149		—			113,299
Other accrued liabilities		32,837		42,062		76,327		—			151,226
Total current liabilities		66,949		205,675		143,753		—			416,377
Long-term debt		3,159,375		—		303,940		(303,940	)		3,159,375
Deferred tax liabilities – noncurrent		—		31,874		50,339		(1,841	)		80,372
Other liabilities		—		107,866		46,401		—			154,267
Total liabilities		3,226,324		345,415		544,433		(305,781	)		3,810,391
Redeemable noncontrolling interests		—		—		28,806		—			28,806
Total equity		2,333,307		3,260,729		1,930,042		(5,190,771	)		2,333,307
Total liabilities and equity	$	5,559,631	$	3,606,144	$	2,503,281	$	(5,496,552	)	$	6,172,504

Summary of Condensed Consolidating Statement of Comprehensive Income (Loss)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended June 30, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	480,250	$	309,112		$	—		$	789,362
Salaries, wages and benefits		4,182			254,656		171,381			—			430,219
Professional fees		—			26,340		32,089			—			58,429
Supplies		—			20,078		10,836			—			30,914
Rents and leases		—			8,716		11,703			—			20,419
Other operating expenses		—			61,519		33,158			—			94,677
Depreciation and amortization		—			20,017		21,060			—			41,077
Interest expense, net		20,138			23,486		4,986			—			48,610
Transaction-related expenses		—			4,578		634			—			5,212
Total expenses		24,320			419,390		285,847			—			729,557
(Loss) income before income taxes		(24,320	)		60,860		23,265			—			59,805
Equity in earnings of subsidiaries		65,884			—		—			(65,884	)		—
(Benefit from) provision for income taxes		(6,637	)		25,298		(7,057	)		—			11,604
Net income (loss)		48,201			35,562		30,322			(65,884	)		48,201
Net income attributable to noncontrolling interests		—			—		(61	)		—			(61	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	48,201		$	35,562	$	30,261		$	(65,884	)	$	48,140
Other comprehensive income:
Foreign currency translation loss		—			—		(50,618	)		—			(50,618	)
Gain on derivative instruments		17,587			—		—			—			17,587
Other comprehensive income (loss)		17,587			—		(50,618	)		—			(33,031	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	65,788		$	35,562	$	(20,357	)	$	(65,884	)	$	15,109

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	453,782	$	311,956		$	—		$	765,738
Salaries, wages and benefits		7,129			239,999		169,613			—			416,741
Professional fees		—			24,677		28,784			—			53,461
Supplies		—			19,292		10,841			—			30,133
Rents and leases		—			8,311		11,925			—			20,236
Other operating expenses		—			55,258		32,024			—			87,282
Depreciation and amortization		—			18,611		21,317			—			39,928
Interest expense, net		15,465			23,602		6,745			—			45,812
Transaction-related expenses		—			2,671		216			—			2,887
Total expenses		22,594			392,421		281,465			—			696,480
(Loss) income before income taxes		(22,594	)		61,361		30,491			—			69,258
Equity in earnings of subsidiaries		75,752			—		—			(75,752	)		—
(Benefit from) provision for income taxes		(5,732	)		11,442		4,658			—			10,368
Net income (loss)		58,890			49,919		25,833			(75,752	)		58,890
Net loss attributable to noncontrolling interests		—			—		(54	)		—			(54	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	58,890		$	49,919	$	25,779		$	(75,752	)	$	58,836
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(143,599	)		—			(143,599	)
Gain on derivative instruments		29,107			—		—			—			29,107
Other comprehensive income (loss)		29,107			—		(143,599	)		—			(114,492	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	87,997		$	49,919	$	(117,820	)	$	(75,752	)	$	(55,656	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Six Months Ended June 30, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	940,068	$	609,911		$	—		$	1,549,979
Salaries, wages and benefits		10,283			509,598		339,917			—			859,798
Professional fees		—			51,708		63,728			—			115,436
Supplies		—			39,462		21,409			—			60,871
Rents and leases		—			17,119		23,607			—			40,726
Other operating expenses		—			120,909		67,633			—			188,542
Depreciation and amortization		—			39,622		42,035			—			81,657
Interest expense, net		39,716			46,504		10,520			—			96,740
Transaction-related expenses		—			7,796		1,737			—			9,533
Total expenses		49,999			832,718		570,586			—			1,453,303
(Loss) income before income taxes		(49,999	)		107,350		39,325			—			96,676
Equity in earnings of subsidiaries		114,041			—		—			(114,041	)		—
(Benefit from) provision for income taxes		(13,670	)		42,363		(9,729	)		—			18,964
Net income (loss)		77,712			64,987		49,054			(114,041	)		77,712
Net gain attributable to noncontrolling interests		—			—		(101	)		—			(101	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	77,712		$	64,987	$	48,953		$	(114,041	)	$	77,611
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(6,137	)		—			(6,137	)
Gain on derivative instruments		8,897			—		—			—			8,897
Other comprehensive income (loss)		8,897			—		(6,137	)		—			2,760
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	86,609		$	64,987	$	42,816		$	(114,041	)	$	80,371

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Six Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	889,407	$	618,572		$	—			1,507,979
Salaries, wages and benefits		14,048			479,051		335,170			—			828,269
Professional fees		—			48,948		58,531			—			107,479
Supplies		—			38,004		21,493			—			59,497
Rents and leases		—			16,550		23,974			—			40,524
Other operating expenses		—			111,428		64,085			—			175,513
Depreciation and amortization		—			36,783		42,918			—			79,701
Interest expense, net		30,082			47,186		13,787			—			91,055
Debt extinguishment costs		940			—		—			—			940
Transaction-related expenses		—			6,680		975			—			7,655
Total expenses		45,070			784,630		560,933			—			1,390,633
(Loss) income before income taxes		(45,070	)		104,777		57,639			—			117,346
Equity in earnings of subsidiaries		143,350			—		—			(143,350	)		—
(Benefit from) provision for income taxes		(11,484	)		11,319		7,747			—			7,582
Net income (loss)		109,764			93,458		49,892			(143,350	)		109,764
Net income attributable to noncontrolling interests		—			—		(109	)		—			(109	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	109,764		$	93,458	$	49,783		$	(143,350	)	$	109,655
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(50,819	)		—			(50,819	)
Gain on derivative instruments		9,054			—		—			—			9,054
Other comprehensive income (loss)		9,054			—		(50,819	)		—			(41,765	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	118,818		$	93,458	$	(1,036	)	$	(143,350	)	$	67,890

Summary of Condensed Consolidating Statement of Cash Flows

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	77,712		$	64,987		$	49,054		$	(114,041	)	$	77,712
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(114,041	)		—			—			114,041			—
Depreciation and amortization		—			39,622			42,035			—			81,657
Amortization of debt issuance costs		5,887			—			—			—			5,887
Equity-based compensation expense		10,283			—			—			—			10,283
Deferred income taxes		(198	)		(73	)		66			—			(205	)
Other		2,126			321			(52	)		—			2,395
Change in operating assets and liabilities:
Accounts receivable, net		—			(24,767	)		(2,902	)		—			(27,669	)
Other current assets		—			(11,029	)		438			—			(10,591	)
Other assets		3,097			(714	)		1,375			(3,097	)		661
Accounts payable and other accrued liabilities		—			942			(12,002	)		—			(11,060	)
Accrued salaries and benefits		—			(4,628	)		1,396			—			(3,232	)
Other liabilities		—			5,558			(2,710	)		—			2,848
Net cash (used in) provided by operating activities		(15,134	)		70,219			76,698			(3,097	)		128,686
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(44,900	)		—			—			(44,900	)
Cash paid for capital expenditures		—			(93,952	)		(45,176	)		—			(139,128	)
Cash paid for real estate acquisitions		—			(4,448	)		—			—			(4,448	)
Other		—			6,402			4,092			—			10,494
Net cash used in investing activities		—			(136,898	)		(41,084	)		—			(177,982	)
Financing activities:
Borrowings on revolving credit facility		76,573			—			—			—			76,573
Principal payments on revolving credit facility		(11,573	)		—			—			—			(11,573	)
Principal payments on long-term debt		(16,492	)		—			(3,097	)		3,097			(16,492	)
Common stock withheld for minimum statutory taxes, net		(1,615	)		—			—			—			(1,615	)
Other		(2,375	)		(889	)		(1,081	)		—			(4,345	)
Cash (used in) provided by intercompany activity		(29,384	)		65,361			(35,977	)		—			—
Net provided by (used in) in financing activities		15,134			64,472			(40,155	)		3,097			42,548
Effect of exchange rate changes on cash		—			—			(221	)		—			(221	)
Net decrease in cash and cash equivalents		—			(2,207	)		(4,762	)		—			(6,969	)
Cash and cash equivalents at beginning of the period		—			32,471			18,039			—			50,510
Cash and cash equivalents at end of the period	$	—		$	30,264		$	13,277		$	—		$	43,541

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	109,764		$	93,458		$	49,892		$	(143,350	)	$	109,764
Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities:
Equity in earnings of subsidiaries		(143,350	)		—			—			143,350			—
Depreciation and amortization		—			36,783			42,918			—			79,701
Amortization of debt issuance costs		5,326			—			(202	)		—			5,124
Equity-based compensation expense		14,048			—			—			—			14,048
Deferred income taxes		1,438			(5,843	)		427			—			(3,978	)
Debt extinguishment costs		940			—			—			—			940
Other		240			1,149			(349	)		—			1,040
Change in operating assets and liabilities:
Accounts receivable, net		—			(23,064	)		(3,040	)		—			(26,104	)
Other current assets		—			12,197			(2,244	)		—			9,953
Other assets		4,514			2,689			72			(4,514	)		2,761
Accounts payable and other accrued liabilities		—			27,859			(6,793	)		—			21,066
Accrued salaries and benefits		—			4,487			(123	)		—			4,364
Other liabilities		—			3,002			(3,795	)		—			(793	)
Net cash provided by (used in) continuing operating activities		(7,080	)		152,717			76,763			(4,514	)		217,886
Net cash used in discontinued operating activities		—			(572	)		—			—			(572	)
Net cash provided by (used in) operating activities		(7,080	)		152,145			76,763			(4,514	)		217,314
Investing activities:
Cash paid for capital expenditures		—			(97,186	)		(64,369	)		—			(161,555	)
Cash paid for real estate acquisitions		—			(8,857	)		—			—			(8,857	)
Other		—			(5,759	)		2,422			—			(3,337	)
Net cash used in investing activities		—			(111,802	)		(61,947	)		—			(173,749	)
Financing activities:
Principal payments on long-term debt		(23,246	)		(169	)		(4,345	)		4,514			(23,246	)
Common stock withheld for minimum statutory taxes, net		(2,134	)		—			—			—			(2,134	)
Other		(1,742	)		(1,924	)		(1,506	)		—			(5,172	)
Cash provided by (used in) intercompany activity		34,202			(25,131	)		(9,071	)		—			—
Net (used in) provided by in financing activities		7,080			(27,224	)		(14,922	)		4,514			(30,552	)
Effect of exchange rate changes on cash		—			—			(840	)		—			(840	)
Net increase (decrease) in cash and cash equivalents		—			13,119			(946	)		—			12,173
Cash and cash equivalents at beginning of the period		—			46,860			20,430			—			67,290
Cash and cash equivalents at end of the period	$	—		$	59,979		$	19,484		$	—		$	79,463

Revenue - Schedule of U.S. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Revenue	$ 789,362	$ 765,738	$ 1,549,979	$ 1,507,979
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	509,813	481,470	997,773	943,875
U.S. Facilities [Member] \| Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	229,128	203,535	445,725	399,426
U.S. Facilities [Member] \| Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	201,269	192,894	394,304	377,429
U.S. Facilities [Member] \| Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	74,084	74,133	147,308	145,690
U.S. Facilities [Member] \| Outpatient Community-Based Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 5,332	$ 10,908	$ 10,436	$ 21,330

Revenue - Schedule of U.S. Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 789,362	$ 765,738	$ 1,549,979	$ 1,507,979
U.S. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 509,813	$ 481,470	$ 997,773	$ 943,875
Revenue, Percentage	100.00%	100.00%	100.00%	100.00%
U.S. Facilities [Member] \| Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 146,917	$ 147,279	$ 286,344	$ 284,898
Revenue, Percentage	28.80%	30.60%	28.70%	30.20%
U.S. Facilities [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 73,505	$ 69,343	$ 146,121	$ 136,557
Revenue, Percentage	14.40%	14.40%	14.60%	14.50%
U.S. Facilities [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 255,070	$ 225,732	$ 494,261	$ 439,068
Revenue, Percentage	50.00%	46.90%	49.50%	46.50%
U.S. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 29,624	$ 33,379	$ 61,356	$ 70,286
Revenue, Percentage	5.80%	6.90%	6.20%	7.40%
U.S. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 4,697	$ 5,737	$ 9,691	$ 13,066
Revenue, Percentage	1.00%	1.20%	1.00%	1.40%

Revenue - Schedule of U.K. Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 789,362	$ 765,738	$ 1,549,979	$ 1,507,979
U.K. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 279,549	$ 284,268	$ 552,206	$ 564,104
Revenue, Percentage	100.00%	100.00%	100.00%	100.00%
U.K. Facilities [Member] \| U.K. Public Funded Sources [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 252,332	$ 256,881	$ 497,745	$ 510,175
Revenue, Percentage	90.30%	90.40%	90.10%	90.40%
U.K. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 26,651	$ 27,272	$ 53,465	$ 52,340
Revenue, Percentage	9.50%	9.60%	9.70%	9.30%
U.K. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 566	$ 115	$ 996	$ 1,589
Revenue, Percentage	0.20%	0.00%	0.20%	0.30%

Revenue - Summary of the Activity in Unearned Revenue (Detail) - U.K. Facilities [Member] - Unearned Revenue [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 31,239
Payments received	87,690
Revenue recognized	(83,456)
Foreign currency translation loss	(747)
Ending Balance	$ 34,726

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$ 48,140	$ 29,471	$ (331,637)	$ 46,232	$ 58,836	$ 50,819	$ 77,611	$ 109,655
Denominator:
Weighted average shares outstanding for basic earnings per share	87,618				87,303		87,562	87,205
Effect of dilutive instruments	219				164		208	146
Shares used in computing diluted earnings per common share	87,837				87,467		87,770	87,351
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.55				$ 0.67		$ 0.89	$ 1.26
Diluted	$ 0.55				$ 0.67		$ 0.88	$ 1.26

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Acquisitions - Additional Information (Detail) $ in Millions	Apr. 01, 2019 USD ($) Bed	Feb. 15, 2019 USD ($) Bed Center	Jun. 30, 2019 Bed
Business Acquisition [Line Items]
Number of beds \| Bed			18,200
Bradford [Member]
Business Acquisition [Line Items]
Number of beds \| Bed	46
Business acquisition cash consideration \| $	$ 4.5
Whittier Pavilion [Member] \| Massachusetts [Member]
Business Acquisition [Line Items]
Number of beds \| Bed		71
Business acquisition cash consideration \| $		$ 17.9
Mission Treatment [Member] \| California, Nevada, Arizona and Oklahoma [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration \| $		$ 22.5
Number of comprehensive treatment centers operates \| Center		9

Acquisitions - Transaction Related Expenses as Incurred (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Business Combinations [Abstract]
Termination, restructuring and strategic review costs	$ 4,792	$ 2,009	$ 8,317	$ 5,401
Legal, accounting and other acquisition-related costs	420	878	1,216	2,254
Transaction-related expenses	$ 5,212	$ 2,887	$ 9,533	$ 7,655

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,707,553	$ 3,593,751
Less: accumulated depreciation	(543,477)	(485,985)
Property and equipment, net	3,164,076	3,107,766
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	446,795	430,771
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,591,815	2,423,594
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	469,107	444,538
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 199,836	$ 294,848

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,247	$ 3,247
Intangible assets not subject to amortization, Gross Carrying Amount	89,613	88,990
Total	92,860	92,237
Intangible assets subject to amortization, Accumulated Amortization	(3,247)	(3,247)
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(3,247)	(3,247)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	12,599	12,343
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	60,039	60,109
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	16,975	16,538
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(2,100)	(2,100)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,147	1,147
Intangible assets subject to amortization, Accumulated Amortization	$ (1,147)	$ (1,147)

Leases - Additional Information (Detail) - USD ($) $ in Thousands		6 Months Ended
	Jan. 01, 2019	Jun. 30, 2019
Lessee Lease Description [Line Items]
Right-of-use assets		$ 536,532
Lease liabilities		$ 569,664
Operating leases remaining lease term	1 year
ASU 2016-02 [Member]
Lessee Lease Description [Line Items]
Right-of-use assets	$ 500,300
Lease liabilities	$ 526,600
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract		5 years
Minimum [Member] \| Copiers and Equipment [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract		1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract		30 years
Maximum [Member] \| Copiers and Equipment [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract		3 years

Leases - Schedule Of Leases On Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	$ 491,551
Total	536,532
Finance lease liabilities	7,095	$ 445
Operating lease liabilities	27,578
Finance lease liabilities	44,088
Operating lease liabilities	490,903
Total	569,664
Property and Equipment, Net [Member]
Lessee Lease Description [Line Items]
Finance lease right-of-use assets	44,981
Operating Lease Right-of-use Assets [Member]
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	491,551
Other Accrued Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	7,095
Current Portion of Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	27,578
Other Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	44,088
Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	$ 490,903

Leases - Schedule of Weighted-average Remaining Lease Terms and Discount Rates (Detail)	Jun. 30, 2019
Leases [Abstract]
Finance lease, weighted average remaining lease term (years)	7 years 2 months 12 days
Operating lease, weighted average remaining term (years)	19 years 8 months 12 days
Finance lease, weighted average discount rate percent	6.40%
Operating lease, weighted average discount rate percent	6.40%

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Finance lease costs:
Depreciation of leased assets	$ 1,136	$ 2,259
Interest of lease liabilities	999	1,996
Total finance lease costs	2,135	4,255
Operating lease costs	16,237	32,766
Variable lease costs	1,044	1,930
Short term lease costs	1,483	2,930
Other lease costs	1,655	3,100
Total rents and leases	20,419	40,726
Total lease costs	$ 22,554	$ 44,981

Leases - Schedule of Undiscounted Cash Flows for Finance and Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Finance Leases
For the six months ending December 31, 2019	$ 4,137
2020	6,938
2021	35,101
2022	2,193
2023	1,063
Thereafter	26,094
Total minimum lease payments	75,526
Less: amount of lease payments representing interest	24,343
Present value of future minimum lease payments	51,183
Less: Current portion of lease liabilities	7,095	$ 445
Noncurrent lease liabilities	44,088
Operating Leases
For the six months ending December 31, 2019	30,201
2020	58,325
2021	54,702
2022	50,007
2023	46,511
Thereafter	708,139
Total minimum lease payments	947,885
Less: amount of lease payments representing interest	429,404
Present value of future minimum lease payments	518,481
Current portion of operating lease liabilities	27,578
Operating lease liabilities	$ 490,903

Leases - Schedule of Supplemental Data (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 31,212
Operating cash flows for finance leases	1,996
Financing cash flows for finance leases	1,684
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	10,674
Finance leases	$ 1,774

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Sep. 21, 2015
Debt Instrument [Line Items]
Other long-term debt	$ 5,396	$ 5,953
Less: unamortized debt issuance costs, discount and premium	(36,803)	(41,128)
Long-term debt	3,245,763	3,193,487
Less: current portion	(38,895)	(34,112)
Long-term debt	3,206,868	3,159,375
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Senior Secured	356,250	365,750
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	1,365,920	1,372,912
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Senior Secured	65,000
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	$ 390,000	$ 390,000

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($) $ in Thousands										3 Months Ended				6 Months Ended		12 Months Ended
	Feb. 27, 2019	Feb. 06, 2019	Apr. 17, 2018	Mar. 29, 2018	Mar. 22, 2018	Mar. 21, 2018	Dec. 15, 2015	Dec. 31, 2012	Apr. 01, 2011	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2017	Dec. 15, 2014
Debt Instrument [Line Items]
Debt extinguishment costs															$ (940)
Term loan repayments			$ 15,000
Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA																	$ 50,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit				$ 400,000
Tranche B-3 Facility [Member]
Debt Instrument [Line Items]
Term loan repayments			5,100
Tranche B-4 Facilities [Member]
Debt Instrument [Line Items]
Term loan repayments			$ 9,900
Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings														2.50%
Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings														1.50%
Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement								Dec. 31, 2012	Apr. 01, 2011
Amount available under revolving line of credit														$ 422,400
Debt instrument maturity date							Nov. 30, 2021									Feb. 11, 2022
Term loan repayments													$ 1,200
Amended and Restated Senior Credit Facility [Member] \| June 30, 2019 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan principal repayments							$ 4,800
Term loan repayments												$ 1,200
Amended and Restated Senior Credit Facility [Member] \| March 31, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan principal repayments							7,100
Term loan repayments										$ 1,200
Amended and Restated Senior Credit Facility [Member] \| March 31, 2021 to September 30, 2021 [Member]
Debt Instrument [Line Items]
Term loan principal repayments							$ 9,500
Amended and Restated Senior Credit Facility [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments											$ 1,200
Amended and Restated Senior Credit Facility [Member] \| Standby Letters Of Credit [Member]
Debt Instrument [Line Items]
Standby letters of credit outstanding														$ 12,600
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments													$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| June 30, 2019 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan repayments												$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| March 31, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan repayments										$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments											$ 2,300
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Revolving credit facility applicable rate				0.25%
Debt extinguishment costs					$ 900
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit				$ 500,000
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member] \| Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit				$ 380,000
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Basis spread on variable rate														1.00%
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Interest on borrowings					2.50%	2.75%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate														0.50%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Interest on borrowings					1.50%	1.75%
Amended and Restated Senior Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings														2.50%
Eleventh Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement		Feb. 06, 2019
Twelfth Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement	Feb. 27, 2019

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)		6 Months Ended
	Mar. 12, 2013	Jun. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000.0
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		payable semi-annually in arrears on March 15 and September 15 of each year

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)		6 Months Ended
	Jul. 01, 2014	Jun. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000.0
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000.0	$ 375,000,000.0
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes	$ 650,000,000	$ 650,000,000	$ 650,000,000.0
Debt instrument maturity date	Feb. 15, 2023
Interest on the notes	payable semi-annually in arrears on February 15 and August 15 of each year

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)		6 Months Ended
	Feb. 16, 2016	Jun. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000.0
Debt instrument interest rate	6.50%	6.50%	6.50%
Debt instrument maturity date	Mar. 01, 2024
Interest on the notes		payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016

Equity-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	8,200,000		8,200,000
Annual increments in employee grants			25.00%
Equity incentive plan available for future grant	2,855,613		2,855,613
Stock options, contractual term			10 years
Equity-based compensation expense	$ 4,182,000	$ 7,129,000	$ 10,283,000	$ 14,048,000
Unrecognized compensation expense related to unvested options			$ 42,100,000
Vesting period			1 year 3 months 18 days
Warrant outstanding	0		$ 0
Deferred income tax benefit			(205,000)	(3,978,000)
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 1,100,000	$ 1,900,000	$ 2,800,000	$ 3,800,000
Restricted Stock Award [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Restricted Stock Award [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Restricted Stock Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			2 years
Number of shares issuable at the end of the vesting period, percentage			0.00%
Restricted Stock Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Number of shares issuable at the end of the vesting period, percentage			200.00%

Equity-Based Compensation - Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance \| shares	1,199,540	974,566
Options granted \| shares	566,800	374,700
Options exercised \| shares	(42,545)	(20,989)
Options cancelled \| shares	(214,423)	(128,737)
Options outstanding, Ending balance \| shares	1,509,372	1,199,540	974,566
Options exercisable, Ending balance \| shares	571,267	534,164
Options outstanding, Weighted Average Exercise Price, Beginning balance \| $ / shares	$ 44.64	$ 47.89
Options granted, Weighted Average Exercise Price \| $ / shares	28.25	37.54
Options exercised, Weighted Average Exercise Price \| $ / shares	20.55	17.83
Options cancelled, Weighted Average Exercise Price \| $ / shares	42.49	50.83
Options outstanding, Weighted Average Exercise Price, Ending balance \| $ / shares	39.44	44.64	$ 47.89
Options exercisable, Weighted Average Exercise Price, Ending balance \| $ / shares	$ 47.60	$ 44.98
Options outstanding, Weighted Average Remaining Contractual Term	7 years 11 months 23 days	7 years 3 months 3 days	7 years 5 months 15 days
Options granted, Weighted Average Remaining Contractual Term	9 years 8 months 8 days	9 years 2 months 15 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 2 months 15 days	5 years 8 months 23 days
Options outstanding, Aggregate Intrinsic Value \| $	$ 1,855	$ 2,717	$ 3,802
Options granted, Aggregate Intrinsic Value \| $	1,196	246
Options exercised, Aggregate Intrinsic Value \| $	457	383
Options cancelled, Aggregate Intrinsic Value \| $	0	0
Options exercisable, Aggregate Intrinsic Value, Ending balance \| $	$ 718	$ 2,386

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 10.45	$ 13.67
Risk-free interest rate	2.40%	2.20%
Expected volatility	38.00%	37.00%
Expected life (in years)	5 years	5 years 1 month 6 days

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	805,057	809,868
Granted, Number of Shares	626,279	480,137
Cancelled, Number of Shares	(289,914)	(88,989)
Vested, Number of Shares	(244,667)	(395,959)
Unvested, Number of Shares/Units, Ending balance	896,755	805,057
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 42.40	$ 50.19
Granted, Weighted Average Grant-Date Fair Value	28.47	36.84
Cancelled, Weighted Average Grant-Date Fair Value	32.35	47.57
Vested, Weighted Average Grant-Date Fair Value	46.85	50.41
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 34.71	$ 42.40

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	484,111	360,909
Granted, Number of Units	168,835	285,358
Cancelled, Number of Units	(267,161)	(89,173)
Vested, Number of Units		(72,983)
Unvested, Number of Shares/Units, Ending balance	385,785	484,111
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 44.52	$ 50.04
Granted, Weighted Average Grant-Date Fair Value	36.01	42.26
Cancelled, Weighted Average Grant-Date Fair Value	45.20	55.44
Vested, Weighted Average Grant-Date Fair Value		49.64
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 40.32	$ 44.52

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Examination [Line Items]
Effective tax rates	19.40%	15.00%	19.60%	6.50%
Discrete tax benefit recorded	$ (11,604)	$ (10,368)	$ (18,964)	$ (7,582)
Change in Accounting Method Accounted for as Change in Estimate [Member]
Income Tax Examination [Line Items]
Discrete tax benefit recorded				$ 10,500

Derivatives - Additional Information (Detail)	1 Months Ended
Derivatives - Additional Information (Detail)	May 31, 2016 USD ($)	May 31, 2016 GBP (£)	Jun. 30, 2019 USD ($)	Dec. 31, 2018 USD ($)	May 31, 2016 GBP (£)
Derivative [Line Items]
Cross currency swap assets			$ 73,000,000.0	$ 60,500,000
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000.0				£ 449,300,000
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 24,700,000
Derivative exchange rate	1.45				1.45

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	$ 5,396	$ 5,953
Derivative instrument assets	72,965	60,524
Carrying Amount [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	5,396	5,953
Derivative instrument assets	72,965	60,524
Carrying Amount [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Secured	1,766,191	1,715,338
Carrying Amount [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	148,951	148,657
Carrying Amount [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	297,348	296,946
Carrying Amount [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	644,019	643,289
Carrying Amount [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	383,858	383,304
Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Derivative instrument assets	72,965	60,524
Other long-term debt	5,396	5,953
Fair Value [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,766,191	1,715,338
Fair Value [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	148,951	147,542
Fair Value [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	298,835	283,583
Fair Value [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	645,484	609,516
Fair Value [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	$ 400,172	$ 369,888

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2019 USD ($)	Sep. 30, 2018 Facility	Jun. 30, 2019 USD ($)
Loss Contingencies [Line Items]
Maximum professional liability aggregate policy limit			$ 75,000,000.0
West Virginia [Member]
Loss Contingencies [Line Items]
Number of comprehensive treatment centers operate \| Facility		7
Amount paid to government	$ 17,000,000.0
Maximum [Member]
Loss Contingencies [Line Items]
Maximum self insured professional liability limit per claim			3,000,000.0
Minimum [Member]
Loss Contingencies [Line Items]
Maximum professional liability retention limit			$ 3,000,000.0

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Noncontrolling Interest [Abstract]
Beginning Balance	$ 28,806
Acquisition of redeemable noncontrolling interests	3,300
Net income attributable to noncontrolling interests	101
Ending Balance	$ 32,207

Other Current Assets - Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 19,963	$ 30,802
Other receivables	19,005	19,205
Cost report receivable	12,594	10,340
Workers’ compensation deposits – current portion	10,000	10,000
Income taxes receivable	9,727	2,380
Inventory	6,076	5,055
Insurance receivable – current portion	2,049	2,049
Other	2,050	1,989
Other current assets	$ 81,464	$ 81,820

Other Accrued Liabilities - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accounts Payable And Accrued Liabilities Current [Abstract]
Accrued expenses	$ 39,824	$ 44,938
Unearned income	35,235	32,154
Accrued interest	33,417	32,838
Income taxes payable	8,047	3,041
Finance lease liabilities	7,095	445
Accrued property taxes	6,077	4,136
Insurance liability – current portion	4,956	4,956
Accrued legal settlements		22,076
Other	3,468	6,642
Other accrued liabilities	$ 138,119	$ 151,226

Segment Information - Summary of Reconciliation of Segment EBITDA to Income before Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Revenue	$ 789,362	$ 765,738	$ 1,549,979	$ 1,507,979
Segment EBITDA	158,886	165,014	294,889	310,745
Equity-based compensation expense	(4,182)	(7,129)	(10,283)	(14,048)
Transaction-related expenses	(5,212)	(2,887)	(9,533)	(7,655)
Debt extinguishment costs				(940)
Interest expense, net	(48,610)	(45,812)	(96,740)	(91,055)
Depreciation and amortization	(41,077)	(39,928)	(81,657)	(79,701)
Income before income taxes	59,805	69,258	96,676	117,346
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	509,813	481,470	997,773	943,875
U.S. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue	509,813	481,470	997,773	943,875
Segment EBITDA	135,396	130,002	254,404	247,126
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	279,549	284,268	552,206	564,104
U.K. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue	279,549	284,268	552,206	564,104
Segment EBITDA	45,835	54,194	85,891	105,346
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Segment Reporting Information [Line Items]
Segment EBITDA	$ (22,345)	$ (19,182)	$ (45,406)	$ (41,727)

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Goodwill:
Beginning balance	$ 2,396,412
Increase from 2019 acquisitions	36,528
Increase from contribution of redeemable noncontrolling interests	3,300
Foreign currency translation loss	(1,215)
Ending balance	2,435,025
U.S. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Beginning balance	2,044,837
Increase from 2019 acquisitions	36,528
Increase from contribution of redeemable noncontrolling interests	3,300
Ending balance	2,084,665
U.K. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Beginning balance	351,575
Foreign currency translation loss	(1,215)
Ending balance	$ 350,360

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Segment Reporting Asset Reconciling Item [Line Items]
Property and equipment, net	$ 3,164,076	$ 3,107,766
Operating Segment [Member] \| U.S. Facilities [Member]
Segment Reporting Asset Reconciling Item [Line Items]
Property and equipment, net	1,400,000	1,400,000
Operating Segment [Member] \| U.K. Facilities [Member]
Segment Reporting Asset Reconciling Item [Line Items]
Property and equipment, net	1,700,000	1,700,000
Corporate Reconciling Items and Eliminations [Member] \| Corporate and Other [Member]
Segment Reporting Asset Reconciling Item [Line Items]
Property and equipment, net	$ 49,300	$ 44,900

Accumulated Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 2,403,343	$ 2,701,619	$ 2,333,307	$ 2,572,871
Foreign currency translation (loss) gain	(50,618)	(143,599)	(6,137)	(50,819)
Gain on derivative instruments, net of tax of $5.7 million	17,587	29,107	8,897	9,054
Balance	2,422,346	2,653,301	2,422,346	2,653,301
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(504,528)
Foreign currency translation (loss) gain			(6,143)
Balance	(510,671)		(510,671)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			43,966
Gain on derivative instruments, net of tax of $5.7 million			8,897
Balance	52,863		52,863
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(1,815)
Foreign currency translation (loss) gain			6
Balance	(1,809)		(1,809)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(426,586)	(301,391)	(462,377)	(374,118)
Balance	$ (459,617)	$ (415,883)	$ (459,617)	$ (415,883)

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 43,541		$ 50,510		$ 79,463		$ 67,290
Accounts receivable, net	346,489		318,087
Other current assets	81,464		81,820
Total current assets	471,494		450,417
Property and equipment, net	3,164,076		3,107,766
Goodwill	2,435,025		2,396,412
Intangible assets, net	89,613		88,990
Deferred tax assets	3,404		3,468
Derivative instrument assets	72,965		60,524
Operating lease right-of-use assets	491,551
Other assets	62,290		64,927
Total assets	6,790,418		6,172,504
Current liabilities:
Current portion of long-term debt	38,895		34,112
Accounts payable	115,651		117,740
Accrued salaries and benefits	110,445		113,299
Current portion of operating lease liabilities	27,578
Other accrued liabilities	138,119		151,226
Total current liabilities	430,688		416,377
Long-term debt	3,206,868		3,159,375
Deferred tax liabilities	83,096		80,372
Operating lease liabilities	490,903
Other liabilities	124,310		154,267
Total liabilities	4,335,865		3,810,391
Redeemable noncontrolling interests	32,207		28,806
Total equity	2,422,346	$ 2,403,343	2,333,307	$ 2,680,249	2,653,301	$ 2,701,619	2,572,871
Total liabilities and equity	6,790,418		6,172,504
Consolidating Adjustments [Member]
Current assets:
Deferred tax assets	(2,038)		(1,841)
Investment in subsidiaries	(5,374,016)		(5,190,771)
Other assets	(249,138)		(303,940)
Total assets	(5,625,192)		(5,496,552)
Current liabilities:
Long-term debt	(249,138)		(303,940)
Deferred tax liabilities	(2,038)		(1,841)
Total liabilities	(251,176)		(305,781)
Total equity	(5,374,016)		(5,190,771)
Total liabilities and equity	(5,625,192)		(5,496,552)
Parent [Member]
Current assets:
Deferred tax assets	2,038		1,841
Derivative instrument assets	72,965		60,524
Investment in subsidiaries	5,374,016		5,190,771
Other assets	252,507		306,495
Total assets	5,701,526		5,559,631
Current liabilities:
Current portion of long-term debt	38,895		34,112
Other accrued liabilities	33,417		32,837
Total current liabilities	72,312		66,949
Long-term debt	3,206,868		3,159,375
Total liabilities	3,279,180		3,226,324
Total equity	2,422,346		2,333,307
Total liabilities and equity	5,701,526		5,559,631
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	30,264		32,471		59,979		46,860
Accounts receivable, net	278,255		248,218
Other current assets	67,790		60,160
Total current assets	376,309		340,849
Property and equipment, net	1,296,263		1,219,803
Goodwill	1,991,905		1,936,057
Intangible assets, net	58,355		56,611
Operating lease right-of-use assets	95,880
Other assets	53,419		52,824
Total assets	3,872,131		3,606,144
Current liabilities:
Accounts payable	81,388		79,463
Accrued salaries and benefits	80,563		84,150
Current portion of operating lease liabilities	16,862
Other accrued liabilities	21,875		42,062
Total current liabilities	200,688		205,675
Deferred tax liabilities	36,334		31,874
Operating lease liabilities	84,286
Other liabilities	106,832		107,866
Total liabilities	428,140		345,415
Total equity	3,443,991		3,260,729
Total liabilities and equity	3,872,131		3,606,144
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	13,277		18,039		$ 19,484		$ 20,430
Accounts receivable, net	68,234		69,869
Other current assets	13,674		21,660
Total current assets	95,185		109,568
Property and equipment, net	1,867,813		1,887,963
Goodwill	443,120		460,355
Intangible assets, net	31,258		32,379
Deferred tax assets	3,404		3,468
Operating lease right-of-use assets	395,671
Other assets	5,502		9,548
Total assets	2,841,953		2,503,281
Current liabilities:
Accounts payable	34,263		38,277
Accrued salaries and benefits	29,882		29,149
Current portion of operating lease liabilities	10,716
Other accrued liabilities	82,827		76,327
Total current liabilities	157,688		143,753
Long-term debt	249,138		303,940
Deferred tax liabilities	48,800		50,339
Operating lease liabilities	406,617
Other liabilities	17,478		46,401
Total liabilities	879,721		544,433
Redeemable noncontrolling interests	32,207		28,806
Total equity	1,930,025		1,930,042
Total liabilities and equity	$ 2,841,953		$ 2,503,281

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Condensed Financial Statements, Captions [Line Items]
Revenue	$ 789,362				$ 765,738		$ 1,549,979	$ 1,507,979
Salaries, wages and benefits	430,219				416,741		859,798	828,269
Professional fees	58,429				53,461		115,436	107,479
Supplies	30,914				30,133		60,871	59,497
Rents and leases	20,419				20,236		40,726	40,524
Other operating expenses	94,677				87,282		188,542	175,513
Depreciation and amortization	41,077				39,928		81,657	79,701
Interest expense, net	48,610				45,812		96,740	91,055
Debt extinguishment costs								940
Transaction-related expenses	5,212				2,887		9,533	7,655
Total expenses	729,557				696,480		1,453,303	1,390,633
(Loss) income before income taxes	59,805				69,258		96,676	117,346
(Benefit from) provision for income taxes	11,604				10,368		18,964	7,582
Net income	48,201				58,890		77,712	109,764
Net income (loss) attributable to noncontrolling interests	(61)				(54)		(101)	(109)
Net income attributable to Acadia Healthcare Company, Inc.	48,140	$ 29,471	$ (331,637)	$ 46,232	58,836	$ 50,819	77,611	109,655
Other comprehensive income:
Foreign currency translation loss	(50,618)				(143,599)		(6,137)	(50,819)
Gain on derivative instruments	17,587				29,107		8,897	9,054
Other comprehensive (loss) income	(33,031)	$ 35,791	$ (21,915)	$ (24,579)	(114,492)	$ 72,727	2,760	(41,765)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	15,109				(55,656)		80,371	67,890
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries	(65,884)				(75,752)		(114,041)	(143,350)
Net income	(65,884)				(75,752)		(114,041)	(143,350)
Net income attributable to Acadia Healthcare Company, Inc.	(65,884)				(75,752)		(114,041)	(143,350)
Other comprehensive income:
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	(65,884)				(75,752)		(114,041)	(143,350)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits	4,182				7,129		10,283	14,048
Interest expense, net	20,138				15,465		39,716	30,082
Debt extinguishment costs								940
Total expenses	24,320				22,594		49,999	45,070
(Loss) income before income taxes	(24,320)				(22,594)		(49,999)	(45,070)
Equity in earnings of subsidiaries	65,884				75,752		114,041	143,350
(Benefit from) provision for income taxes	(6,637)				(5,732)		(13,670)	(11,484)
Net income	48,201				58,890		77,712	109,764
Net income attributable to Acadia Healthcare Company, Inc.	48,201				58,890		77,712	109,764
Other comprehensive income:
Gain on derivative instruments	17,587				29,107		8,897	9,054
Other comprehensive (loss) income	17,587				29,107		8,897	9,054
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	65,788				87,997		86,609	118,818
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue	480,250				453,782		940,068	889,407
Salaries, wages and benefits	254,656				239,999		509,598	479,051
Professional fees	26,340				24,677		51,708	48,948
Supplies	20,078				19,292		39,462	38,004
Rents and leases	8,716				8,311		17,119	16,550
Other operating expenses	61,519				55,258		120,909	111,428
Depreciation and amortization	20,017				18,611		39,622	36,783
Interest expense, net	23,486				23,602		46,504	47,186
Transaction-related expenses	4,578				2,671		7,796	6,680
Total expenses	419,390				392,421		832,718	784,630
(Loss) income before income taxes	60,860				61,361		107,350	104,777
(Benefit from) provision for income taxes	25,298				11,442		42,363	11,319
Net income	35,562				49,919		64,987	93,458
Net income attributable to Acadia Healthcare Company, Inc.	35,562				49,919		64,987	93,458
Other comprehensive income:
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	35,562				49,919		64,987	93,458
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue	309,112				311,956		609,911	618,572
Salaries, wages and benefits	171,381				169,613		339,917	335,170
Professional fees	32,089				28,784		63,728	58,531
Supplies	10,836				10,841		21,409	21,493
Rents and leases	11,703				11,925		23,607	23,974
Other operating expenses	33,158				32,024		67,633	64,085
Depreciation and amortization	21,060				21,317		42,035	42,918
Interest expense, net	4,986				6,745		10,520	13,787
Transaction-related expenses	634				216		1,737	975
Total expenses	285,847				281,465		570,586	560,933
(Loss) income before income taxes	23,265				30,491		39,325	57,639
(Benefit from) provision for income taxes	(7,057)				4,658		(9,729)	7,747
Net income	30,322				25,833		49,054	49,892
Net income (loss) attributable to noncontrolling interests	(61)				(54)		(101)	(109)
Net income attributable to Acadia Healthcare Company, Inc.	30,261				25,779		48,953	49,783
Other comprehensive income:
Foreign currency translation loss	(50,618)				(143,599)		(6,137)	(50,819)
Other comprehensive (loss) income	(50,618)				(143,599)		(6,137)	(50,819)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$ (20,357)				$ (117,820)		$ 42,816	$ (1,036)

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating activities:
Net income (loss)	$ 48,201	$ 58,890	$ 77,712	$ 109,764
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	41,077	39,928	81,657	79,701
Amortization of debt issuance costs			5,887	5,124
Equity-based compensation expense	4,182	7,129	10,283	14,048
Deferred income taxes			(205)	(3,978)
Debt extinguishment costs				940
Other			2,395	1,040
Change in operating assets and liabilities:
Accounts receivable, net			(27,669)	(26,104)
Other current assets			(10,591)	9,953
Other assets			661	2,761
Accounts payable and other accrued liabilities			(11,060)	21,066
Accrued salaries and benefits			(3,232)	4,364
Other liabilities			2,848	(793)
Net cash provided by continuing operating activities			128,686	217,886
Net cash used in discontinued operating activities				(572)
Net cash provided by operating activities			128,686	217,314
Investing activities:
Cash paid for acquisitions, net of cash acquired			(44,900)
Cash paid for capital expenditures			(139,128)	(161,555)
Cash paid for real estate acquisitions			(4,448)	(8,857)
Other			10,494	(3,337)
Net cash used in investing activities			(177,982)	(173,749)
Financing activities:
Borrowings on revolving credit facility			76,573
Principal payments on revolving credit facility			(11,573)
Principal payments on long-term debt			(16,492)	(23,246)
Common stock withheld for minimum statutory taxes, net			(1,615)	(2,134)
Other			(4,345)	(5,172)
Net cash provided by (used in) financing activities			42,548	(30,552)
Effect of exchange rate changes on cash			(221)	(840)
Net (decrease) increase in cash and cash equivalents			(6,969)	12,173
Cash and cash equivalents at beginning of the period			50,510	67,290
Cash and cash equivalents at end of the period	43,541	79,463	43,541	79,463
Consolidating Adjustments [Member]
Operating activities:
Net income (loss)	(65,884)	(75,752)	(114,041)	(143,350)
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries	65,884	75,752	114,041	143,350
Change in operating assets and liabilities:
Other assets			(3,097)	(4,514)
Net cash provided by continuing operating activities				(4,514)
Net cash provided by operating activities			(3,097)	(4,514)
Financing activities:
Principal payments on long-term debt			3,097	4,514
Net cash provided by (used in) financing activities			3,097	4,514
Parent [Member]
Operating activities:
Net income (loss)	48,201	58,890	77,712	109,764
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries	(65,884)	(75,752)	(114,041)	(143,350)
Amortization of debt issuance costs			5,887	5,326
Equity-based compensation expense			10,283	14,048
Deferred income taxes			(198)	1,438
Debt extinguishment costs				940
Other			2,126	240
Change in operating assets and liabilities:
Other assets			3,097	4,514
Net cash provided by continuing operating activities				(7,080)
Net cash provided by operating activities			(15,134)	(7,080)
Financing activities:
Borrowings on revolving credit facility			76,573
Principal payments on revolving credit facility			(11,573)
Principal payments on long-term debt			(16,492)	(23,246)
Common stock withheld for minimum statutory taxes, net			(1,615)	(2,134)
Other			(2,375)	(1,742)
Cash (used in) provided by intercompany activity			(29,384)	34,202
Net cash provided by (used in) financing activities			15,134	7,080
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income (loss)	35,562	49,919	64,987	93,458
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	20,017	18,611	39,622	36,783
Deferred income taxes			(73)	(5,843)
Other			321	1,149
Change in operating assets and liabilities:
Accounts receivable, net			(24,767)	(23,064)
Other current assets			(11,029)	12,197
Other assets			(714)	2,689
Accounts payable and other accrued liabilities			942	27,859
Accrued salaries and benefits			(4,628)	4,487
Other liabilities			5,558	3,002
Net cash provided by continuing operating activities				152,717
Net cash used in discontinued operating activities				(572)
Net cash provided by operating activities			70,219	152,145
Investing activities:
Cash paid for acquisitions, net of cash acquired			(44,900)
Cash paid for capital expenditures			(93,952)	(97,186)
Cash paid for real estate acquisitions			(4,448)	(8,857)
Other			6,402	(5,759)
Net cash used in investing activities			(136,898)	(111,802)
Financing activities:
Principal payments on long-term debt				(169)
Other			(889)	(1,924)
Cash (used in) provided by intercompany activity			65,361	(25,131)
Net cash provided by (used in) financing activities			64,472	(27,224)
Net (decrease) increase in cash and cash equivalents			(2,207)	13,119
Cash and cash equivalents at beginning of the period			32,471	46,860
Cash and cash equivalents at end of the period	30,264	59,979	30,264	59,979
Combined Non-Guarantors [Member]
Operating activities:
Net income (loss)	30,322	25,833	49,054	49,892
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	21,060	21,317	42,035	42,918
Amortization of debt issuance costs				(202)
Deferred income taxes			66	427
Other			(52)	(349)
Change in operating assets and liabilities:
Accounts receivable, net			(2,902)	(3,040)
Other current assets			438	(2,244)
Other assets			1,375	72
Accounts payable and other accrued liabilities			(12,002)	(6,793)
Accrued salaries and benefits			1,396	(123)
Other liabilities			(2,710)	(3,795)
Net cash provided by continuing operating activities				76,763
Net cash provided by operating activities			76,698	76,763
Investing activities:
Cash paid for capital expenditures			(45,176)	(64,369)
Other			4,092	2,422
Net cash used in investing activities			(41,084)	(61,947)
Financing activities:
Principal payments on long-term debt			(3,097)	(4,345)
Other			(1,081)	(1,506)
Cash (used in) provided by intercompany activity			(35,977)	(9,071)
Net cash provided by (used in) financing activities			(40,155)	(14,922)
Effect of exchange rate changes on cash			(221)	(840)
Net (decrease) increase in cash and cash equivalents			(4,762)	(946)
Cash and cash equivalents at beginning of the period			18,039	20,430
Cash and cash equivalents at end of the period	$ 13,277	$ 19,484	$ 13,277	$ 19,484

Property and Equipment - Additional information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2019 USD ($) Bed	Dec. 31, 2018 USD ($)
Other Assets [Member]
Property, Plant and Equipment [Line Items]
Assets held for sale \| $	$ 10.9	$ 17.0
Residential Treatment Centers [Member] \| Albuquerque, New Mexico [Member]
Property, Plant and Equipment [Line Items]
Number of beds in facilities closed \| Bed	168

Noncontrolling Interests - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2019 Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	5
Non-Wholly Owned Subsidiaries [Member] \| Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	60.00%
Non-Wholly Owned Subsidiaries [Member] \| Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	85.00%

Description of Business and Basis of Presentation - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2019 Facility Bed State
Accounting Policies [Abstract]
Number of facilities \| Facility	595
Number of beds \| Bed	18,200
Number of operating states \| State	40

Recently Issued Accounting Standards - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Change In Accounting Estimate [Line Items]
Right-of-use assets	$ 536,532
Lease liabilities	$ 569,664
ASU 2016-02 [Member]
Change In Accounting Estimate [Line Items]
Right-of-use assets		$ 500,300
Lease liabilities		$ 526,600

Segment Information - Additional Information (Detail)	6 Months Ended
Segment Information - Additional Information (Detail)	Jun. 30, 2019 Facility Bed State
Segment Reporting Information [Line Items]
Number of facilities \| Facility	595
Number of beds \| Bed	18,200
Number of operating states \| State	40
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facility	225
Number of beds \| Bed	9,400
Number of operating states \| State	40
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facility	370
Number of beds \| Bed	8,800

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Assets:
Assets	$ 6,790,418	$ 6,172,504
U.S. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	3,995,903	3,779,040
U.K. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	2,543,030	2,175,809
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Assets:
Assets	$ 251,485	$ 217,655

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Jun. 30, 2019	Dec. 31, 2018	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%